

(A free translation of the original in Portuguese)

Interim financial information 2Q24

Management report	3
Independent auditors' report on the individual and consolidated review of quarterly information interim financial information	5
Statements of financial position	7
Income statements of income	9
Statements of comprehensive income	10
Statements of changes in shareholders' equity	11
Statements of cash flows – indirect method	12
Statements of value added	13
Notes to the individual and consolidated interim financial information	14

(A free translation of the original in Portuguese)

Gross and net operational income revenue from operations

In 2Q24, the Company recorded gross income revenue of R\$4.3 billion vs. R\$3.9 billion in 2Q23, an increase of 10%. Net income revenue of for the period was R\$4.0 billion vs. R\$3.6 billion, up 9% vs. 2Q23; this increase was, lower than the gross income revenue increase mainly due to the revision of the statistical disallowances model started from in 4Q23 in BU1.

Cost of services rendered Operational costs (COGS)

Cost of services rendered Operational costs in 2Q24 totaled R\$2.8 billion vs. R\$2.5 billion no 2Q23, up 11%, mainly due to the increase in transaction volumes along with the effects of inflation of in the period.

General and administrative expenses (SG&A)

General and administrative expenses in 2Q24 totaled R\$818 million vs. R\$843 million in 2Q23, down by 3%, mainly due reflecting to the Company's actions to reorganize streamline the organizational structure and adapting the market policies, relocating on and reduction optimizing of occupied buildings and strengthening of processes and controls in general.

Net financial expenses, net

Financial expenses, net in 2Q24 was an expense of R\$451 million, stable compared to 2Q23.

Net loss

Net loss in 2Q24 was R\$101 million, lower by an improvement of 64% vs. 2Q23, mainly due to the increase of the gross income revenue and along with the effect of the rationalization of expense's reduction.

Indebtedness

The Company ended 2Q24 with gross debt of R\$11.4 billion, a decrease of R\$360 million vs. 1Q24, with an average term tenure of 3.9 years and average cost of CDI + 1.66% pay.

At the end of 2Q24, the cash, cash equivalent and securities position was R\$3.0 billion, representing 1.7x of the debts loans falling ended until due through to 2025 of R\$1.8 billion. This position reflects the cash impact of benefitted from the receipt of the AFAC (Advances for future capital) in the amount of R\$1.5 billion and, together with operational and strategic initiatives, it allows the establishment of an increasingly solid has generated a robust financial position.

Therefore, the Company ended 2Q24 with net debt of R\$8.4 billion, showing a reduction of R\$1.2 billion vs. 1Q24.

Capex

Consolidated investments totaled R\$85 million in 2Q24, representing a reduction of 47% in relation to the R\$158 million recorded in 2Q23 and 52% in on the half-yearly comparison basis. This, reflectings the Company's focus on expansion projects with higher returns in the short term, maintenance optimizing of existing assets and technological y services that play an important which are central to its role in operations, and, at the same time, ensuring quality and excellence in the provision of medical-hospital, oncology and diagnostic services.



(A free translation of the original in Portuguese)

Report on review of quarterly information

To the Board of Directors and Stockholders
Diagnósticos da América S.A.

Introduction

We have reviewed the accompanying interim accounting information of Diagnósticos da América S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2024, comprising the balance sheet at that date and the statements of income and comprehensive income for the quarter and six-month period then ended, and the statements of changes in equity and cash flows for the six-month period then ended, and explanatory notes.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21, Interim Financial Reporting, of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34, Interim Financial Reporting issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.



Diagnósticos da América S.A.

Other matters

Statement of value added

The quarterly information referred to above includes the parent company and consolidated statements of value added for the six-month period ended June 30, 2024. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the interim accounting information for the purpose of concluding whether they are reconciled with the interim accounting information and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria established in this accounting standard, and consistent with the parent company and consolidated interim accounting information taken as a whole.

São Paulo, august 14, 2024

PRICEWATERHOUSECOOPERS

PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2SP000160/O-5

Carlos Eduardo Guaraná Mendonça
Contador CRC 1SP196994/O-2

Balance sheet

As of June 30, 2024 and December 31, 2023

(In thousands of reais)

		Parent Company		Consolidated				Parent company		Consolidated	
	Note	06/30/2024	12/31/2023	06/30/2024	12/31/2023		Note	06/30/2024	12/31/2023	06/30/2024	12/31/2023
CURRENT ASSETS						CURRENT LIABILITIES					
Cash and cash equivalents	5	1,871,205	521,440	2,872,701	1,585,194	Suppliers		526,712	628,802	1,319,736	1,538,242
Securities	6	84,036	79,561	113,721	103,815	Loans and financing	11	4,168	4,743	87,520	122,966
Trade accounts receivable	7	1,168,647	1,000,860	4,717,061	3,976,643	Debentures	13	1,253,565	1,194,698	1,354,107	1,395,830
Inventories		161,427	163,717	488,616	450,977	Income tax and social contribution payable		-	-	89,232	26,513
Recoverable taxes		298,805	349,264	658,212	602,040	Social charges and labor obligations		327,372	230,081	860,370	613,597
Derivative financial instruments	24	18	-	13,131	-	Taxes payable		97,519	64,033	309,810	316,818
Related parties	25d	1,857,361	1,259,559	-	-	Payable - acquisition of subsidiaries	14	81,101	78,630	529,706	505,146
Asset from discontinued operation	27	-	-	1,887	-	Dividends and interest on own capital	17d	4	155	34,895	44,320
Other credits		190,836	178,378	323,770	312,845	Derivative financial instruments	24	934	885	934	885
						Provision for unsecured liability	8	134,848	71,609	-	-
						Lease liabilities	12	227,779	182,195	429,095	378,598
						Share-based payment	16	72,039	56,075	72,039	56,075
						Liability from discontinued operation	27	-	-	-	784
						Advance from clients		-	-	6,182	94,028
						Other accounts payable and provisions		320,077	157,315	544,584	547,573
TOTAL CURRENT ASSETS		5,632,335	3,552,779	9,189,099	7,031,514	TOTAL CURRENT LIABILITIES		3,046,118	2,669,221	5,638,210	5,641,375
NON-CURRENT ASSETS						NON-CURRENT LIABILITIES					
NON-CURRENT RECEIVABLES											
Restricted financial investments	14	6,728	6,475	7,388	6,605	Suppliers		16,543	46,738	16,548	46,743
Trade accounts receivable	7	21,063	12,191	27,150	15,937	Loans and financing	11	5,293	7,215	28,867	69,304
Recoverable taxes		71,916	62,104	71,916	62,104	Debentures	13	9,876,546	9,063,337	9,876,546	9,063,337
Derivative financial instruments	24	58,900	-	58,900	7,165	Taxes payable		-	476	87,528	108,014
Judicial deposits	15	52,555	59,653	117,190	118,160	Payable - acquisition of subsidiaries	14	29,489	67,776	723,756	761,802
Deferred taxes	22	979,490	936,030	1,420,383	1,286,050	Derivative financial instruments	24	101,807	23,601	101,807	25,106
Related parties	25b	272,341	236,120	-	-	Tax, social security, labor and civil provisions	15	128,249	109,619	490,580	459,617
Other credits		97,677	103,840	451,763	467,604	Lease liabilities	12	676,313	745,806	2,153,664	2,264,593
						Share-based payment	16	2,397	16,962	2,397	16,962
						Deferred taxes	22	-	-	20,378	13,198
						Related parties	25	1,532,779	250,073	1,537,426	45,212
						Other accounts payable and provisions		22,046	135,653	277,666	364,118
NON-CURRENT RECEIVABLES		1,560,670	1,416,413	2,154,690	1,963,625	TOTAL NON-CURRENT LIABILITIES		12,391,462	10,467,256	15,317,163	13,238,006
						TOTAL LIABILITIES		15,437,580	13,136,477	20,955,373	18,879,381



Balance sheets
As of June 30, 2024 and December 31, 2023
(In thousands of reais)

	Note	Parent Company		Consolidated	
		06/30/2024	12/31/2023	06/30/2024	12/31/2023
Investments	8	10,525,091	10,287,277	3,628	4,175
Property and equipment	9	998,722	1,085,016	3,895,789	4,004,874
Right-of-use	12	867,748	889,855	2,384,254	2,474,055
Intangible assets	10	3,003,843	3,235,564	10,498,989	10,734,957
TOTAL NON-CURRENT ASSETS		16,956,074	16,914,125	18,937,350	19,181,686
TOTAL ASSETS		22,588,409	20,466,904	28,126,449	26,213,200

SHAREHOLDERS' EQUITY

Share capital	17a	17,946,204	17,946,204	17,946,204	17,946,204
Capital reserves		994,265	987,908	994,265	987,908
Treasury shares	17c	(79,376)	(81,258)	(79,376)	(81,258)
Equity valuation adjustment	17b	(9,749,907)	(9,842,648)	(9,749,907)	(9,842,648)
Accumulated deficit	17e	(1,960,357)	(1,679,779)	(1,960,357)	(1,679,779)
TOTAL SHAREHOLDERS' EQUITY		7,150,829	7,330,427	7,150,829	7,330,427
Non-controlling interest		-	-	20,247	3,392
TOTAL SHAREHOLDERS' EQUITY		7,150,829	7,330,427	7,171,076	7,333,819
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		22,588,409	20,466,904	28,126,449	26,213,200

See the accompanying notes to the individual parent company and consolidated quarterly information.

Statement of income

Three and six-month periods ended June 30, 2024 and 2023

(In thousands of reais, unless otherwise indicated)

	Note	Parent Company				Consolidated			
		04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Net operating income	18	1,433,879	2,796,574	1,300,074	2,604,268	3,955,692	7,683,684	3,630,941	7,165,011
Cost of services rendered	19	(939,737)	(1,824,102)	(871,880)	(1,703,224)	(2,815,882)	(5,478,386)	(2,546,474)	(5,029,998)
Gross income		494,142	972,472	428,194	901,044	1,139,810	2,205,298	1,084,467	2,135,013
General and administrative expenses	20	(362,962)	(736,676)	(335,176)	(766,679)	(817,953)	(1,609,702)	(842,566)	(1,596,973)
Other income and (expenses), net		18,013	26,902	(7,553)	(9,100)	23,819	53,325	(26,530)	(16,645)
Equity in results of subsidiaries	8.2	(129,193)	(270,640)	(334,591)	(197,241)	-	-	-	-
Profit before financial result and taxes		20,000	(7,942)	(249,126)	(71,976)	345,676	648,921	215,371	521,395
Financial income	21	80,861	132,675	61,736	111,991	108,563	178,081	112,179	174,689
Financial expenses	21	(199,774)	(406,396)	(31,301)	(488,166)	(559,638)	(1,114,068)	(557,257)	(1,154,629)
Net financial income (expenses)		(118,913)	(273,721)	30,435	(376,175)	(451,075)	(935,987)	(445,078)	(979,940)
Loss before income tax and social contribution		(98,913)	(281,663)	(218,691)	(448,151)	(105,399)	(287,066)	(229,707)	(458,545)
Current income tax and social contribution	22	(30,501)	(42,350)	-	-	(70,064)	(123,275)	16,939	(65,505)
Income tax and social contribution - deferred	22	24,791	43,435	(63,410)	-	75,114	133,682	(71,289)	72,243
Loss for the period from continued operations		(104,623)	(280,578)	(282,101)	(448,151)	(100,349)	(276,659)	(284,057)	(451,807)
Profit (loss) from discontinued operations	27	-	-	-	-	(528)	1,654	-	-
Loss for the period		(104,623)	(280,578)	(282,101)	(448,151)	(100,877)	(275,005)	(284,057)	(451,807)
Profit (loss) attributable to:									
Controlling shareholders		-	-	-	-	(104,623)	(280,578)	(282,101)	(448,151)
Non-controlling shareholders		-	-	-	-	3,746	5,573	(1,956)	(3,656)
Loss for the period		(104,623)	(280,578)	(282,101)	(448,151)	(100,877)	(275,005)	(284,057)	(451,807)
Total earnings per common share									
Basic (in R\$)	17e		(0.37550)		(0.60003)				
Diluted (In reais)	17e		(0.35695)		(0.57688)				
Number of shares - basic (in thousands)	17e		747,218		746,880				
Number of shares - diluted (in thousands)	17e		786,041		776,860				

See the accompanying notes to the individual parent company and consolidated quarterly information.

Statements of comprehensive income
Three and six-month periods ended June 30, 2024 and 2023
(In thousands of reais)

	Parent Company				Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Loss for the period	(104,623)	(280,578)	(282,101)	(448,151)	(100,877)	(275,005)	(284,057)	(451,807)
Effect on translation of financial statements of foreign subsidiaries	36,554	30,637	(17,794)	(39,432)	36,554	30,637	(17,794)	(39,432)
Effect of the adoption of CPC 42 / IAS 29 - Financial Reporting in Hyperinflationary Economies	23,983	92,258	2,434	2,441	23,983	92,258	2,434	2,441
Comprehensive income for the period	(44,086)	(157,683)	(297,461)	(485,142)	(40,340)	(152,110)	(299,417)	(488,798)
Comprehensive income attributable to:								
Controlling shareholders					(44,086)	(157,683)	(297,461)	(485,142)
Non-controlling shareholders					3,746	5,573	(1,956)	(3,656)
Comprehensive income for the period	(40,340)	(152,110)	(299,417)	(488,798)	(40,340)	(152,110)	(299,417)	(488,798)

See the accompanying notes to the individual parent company and consolidated quarterly information.

Statements of changes in shareholders' equity
Six-month periods ended June 30, 2024 and 2023
(In thousands of reais)

	Note	Share capital		Capital reserve		Treasury shares	Accumulated deficit	Equity valuation adjustment	Total parent company	Non-controlling shareholders	Total consolidated
		Share capital	Issue cost	Goodwill reserve	Transactions with share-based payments						
Balance at December 31, 2022		16,302,238	-	432,772	505,574	(39,201)	(448,287)	(9,674,472)	7,078,624	10,777	7,089,401
Capital increase		1,665,701	-	-	-	-	-	-	1,665,701	-	1,665,701
Cost for the issue of shares		-	(21,831)	-	-	-	-	-	(21,831)	-	(21,831)
Treasury shares acquired	17c	-	-	-	-	(109,908)	-	-	(109,908)	-	(109,908)
Transactions among shareholders		-	-	-	-	-	-	(11,204)	(11,204)	3,599	(7,605)
Loss for the period		-	-	-	-	-	(448,151)	-	(448,151)	(3,656)	(451,807)
Other comprehensive income	17b	-	-	-	-	-	-	(36,991)	(36,991)	-	(36,991)
Stock option plan	16	-	-	-	22,876	-	-	-	22,876	-	22,876
Balance at June 30, 2023		17,967,939	(21,831)	432,772	528,450	(149,109)	(896,438)	(9,722,667)	8,139,116	10,720	8,149,836
Balance at December 31, 2023		18,032,489	(86,285)	432,772	555,136	(81,258)	(1,679,779)	(9,842,648)	7,330,427	3,392	7,333,819
Transactions among shareholders		-	-	-	-	-	-	(30,154)	(30,154)	11,282	(18,872)
Loss for the period		-	-	-	-	-	(280,578)	-	(280,578)	5,573	(275,005)
Other comprehensive income	17b	-	-	-	-	-	-	122,895	122,895	-	122,895
Stock option plan	16	-	-	-	6,357	1,882	-	-	8,239	-	8,239
Balance at June 30, 2024		18,032,489	(86,285)	432,772	561,493	(79,376)	(1,960,357)	(9,749,907)	7,150,829	20,247	7,171,076

See the accompanying notes to the individual parent company and consolidated quarterly information.

Cash flow statements
Six-month periods ended June 30, 2024 and 2023

(In thousands of reais)

	Note	Parent Company		Consolidated	
		06/30/2024	06/30/2023	06/30/2024	06/30/2023
Cash flows from operating activities					
Loss before income tax and social contribution		(281,663)	(448,151)	(287,066)	(458,545)
Items not affecting cash:					
Depreciation and amortization	9 10 12	387,256	380,466	657,942	620,386
Tax, social security, labor and civil provisions	15	43,903	33,803	61,534	39,017
Restatement of interest and exchange-rate change from loans and financing, property and equipment, intangible assets and payable - acquisition of subsidiaries		674,690	760,529	760,476	894,513
Results from derivative financial instruments		19,337	11,334	11,884	18,719
Residual write-off of property and equipment, intangible assets and right of use	9 10 12	134,790	1,170	136,975	1,761
Update of option plan		9,638	22,876	9,638	22,876
Equity in results of subsidiaries	8.3	270,640	197,241	-	-
Expected losses from doubtful accounts	7	1,544	9,236	12,075	26,137
Provision (reversal) of disallowances	7	6,970	(6,420)	42,356	(6,532)
Restatement of interest and exchange-rate change from interest earning bank deposits		(4,474)	(73,099)	(4,474)	(70,914)
Reversal of (provision) for loss on inventories		(177)	5,816	(484)	6,890
Interest on lease	12	45,984	44,700	158,922	104,108
(Increase) decrease in assets					
Accounts receivable	7	(185,173)	(115,671)	(806,062)	(735,933)
Inventories		2,467	7,412	(37,155)	5,208
Other current assets		(601,659)	(540,630)	(63,990)	(102,273)
Other non-current assets		(32,975)	(118,812)	6,763	(132,113)
Increase (decrease) in liabilities					
Suppliers		(115,282)	(130,196)	(236,890)	(193,310)
Accounts payable and provisions		(102,277)	(16,050)	(13,652)	(20,513)
Payment of stock option plan	16	-	10,082	-	15,933
Discontinued operation	27	-	-	(1,017)	-
		273,539	35,636	407,775	35,415
Interest paid on loans, financing and debentures	11 13	(576,713)	(754,983)	(598,294)	(804,389)
Payment of lease interest	12	(45,984)	(9,843)	(158,922)	(21,931)
Income tax and social contribution paid	22	-	-	(72,080)	(19,316)
Cash flow used in operating activities		(349,158)	(729,190)	(421,521)	(810,221)
Cash flows from investing activities					
Cash absorbed from subsidiaries in the merger	2.g	7,806	-	-	-
Acquisition of property and equipment	9	(67,397)	(34,226)	(114,357)	(142,847)
Acquisition of intangible assets	10	-	(228,428)	(5,551)	(254,458)
Advance for future capital increase	8.3	(380,164)	(688,900)	-	-
Amount received for sale of property and equipment		1,343	-	1,476	-
Acquisition of subsidiaries' non-controlling shareholders	2.e. 2.f	(31,054)	-	(31,054)	-
Interest earning bank deposits		-	(5,047,632)	(15,224)	(4,779,821)
Redemption of interest earning bank deposits		-	5,549,534	6,683	5,330,895
Cash flow from (invested in) investment activities		(469,466)	(449,652)	(158,027)	153,769
Cash flow from financing activities					
Funding of loans and debentures	11 13	1,710,000	-	1,710,000	-
Payment of loans and debentures	11 13	(902,486)	(115,663)	(1,080,386)	(341,741)
Dividends and interest on own capital paid		(151)	-	(9,425)	-
Repurchase of shares		-	(109,908)	-	(109,908)
Controlling shareholder's capital contribution	25.f	1,500,000	-	1,500,000	-
Capital increase		-	1,643,870	-	1,643,870
Payments of payable - acquisition of subsidiaries	14	(44,486)	(7,898)	(95,187)	(58,761)
Payment of principal - Lease	12	(94,488)	(116,512)	(157,947)	(259,601)
Cash flow from financing activities		2,168,389	1,293,889	1,867,055	873,859
Net increase in cash and cash equivalents		1,349,765	115,047	1,287,507	217,407
Statement of increase in cash and cash equivalents					
At the beginning of the period		521,440	237,856	1,585,194	1,284,992
At the end of the period		1,871,205	352,903	2,872,701	1,502,399
		1,349,765	115,047	1,287,507	217,407

See the accompanying notes to the individual parent company and consolidated quarterly information.

Statements of value added
Six-month periods ended June 30, 2024 and 2023
(In thousands of reais)

		Parent Company		Consolidated	
	Note	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Income					
Sale of goods, products and services	18	3,054,844	2,805,633	8,375,252	7,719,239
Other income		28,039	2,744	71,410	33,654
Recovery of expected losses from doubtful accounts	7	(8,514)	(2,816)	(54,431)	(19,605)
Inputs acquired from third parties					
Cost of products, goods sold and services provided		(1,157,575)	(1,107,057)	(3,538,224)	(3,333,667)
Materials, energy, outsourced services and other		(259,546)	(242,270)	(903,723)	(764,572)
Gross value added		1,657,248	1,456,234	3,950,284	3,635,049
Depreciation and amortization	9 10 12	(387,256)	(380,466)	(657,942)	(620,386)
Net value added generated		1,269,992	1,075,768	3,292,342	3,014,663
Equity in results of subsidiaries	8.3	(270,640)	(197,241)	-	-
Financial income	21	132,675	111,991	178,081	174,689
Total value added payable		1,132,027	990,518	3,470,423	3,189,352
Distribution of value added		1,132,027	990,518	3,470,423	3,189,352
Personnel		840,156	835,462	2,149,137	2,056,798
Salaries		719,794	717,535	1,898,466	1,802,159
Benefits		120,362	117,927	250,671	254,639
Taxes, rates and contributions		188,709	168,094	522,049	518,103
Federal		112,096	100,777	313,977	328,873
State		3,939	-	5,187	4,501
Municipal		72,674	67,317	202,885	184,729
Third-party capital remuneration					
Interest on funding and financing		383,740	435,113	1,074,242	1,066,258
Remuneration of own capital					
Loss for the period		(280,578)	(448,151)	(280,578)	(448,151)
Non-controlling interests in share of loss for the period		-	-	5,573	(3,656)

See the accompanying notes to the individual parent company and consolidated quarterly information.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

1 Operations

Diagnósticos da América S.A. ("DASA" or "Parent Company" or "Company") and, jointly with its subsidiaries ("DASA Group" or "Consolidated") has its registered address at Avenida Juruá, no. 434, Alphaville, CEP 06455-010, city of Barueri, State of São Paulo, Brazil. It is a publicly held corporation registered with the Brazilian Securities Commission (CVM) on November 5, 2004, and trades its shares on the Novo Mercado of B3 S.A. - Brasil, Bolsa, Balcão ("B3") stock market, that market segment being the highest level of corporate governance in the Brazilian capital market for the trading of its securities, under the ticker symbol DASA3.

The Company, through its own operations as well as through its subsidiaries, is engaged in the provision of the following services: (i) outpatient physicians; (ii) diagnostic support assistants for private patients or covered companies; (iii) services to hospitals, medical centers and outpatients; (iv) delivering care services, remote monitoring, population health management, home medical and paramedical services and outpatient medical activities for medical consultations; (v) development and licensing of computer programs; (vi) development and licensing of predictive models using information technology and data science; and (vii) brokerage fee.

2 Main events in the period

(a) Association agreement ("Association Agreement") between DASA and Amil Assistência Médica Internacional S.A. ("Amil")

On June 14, 2024, DASA signed an Association Agreement with Amil, through which Amil will contribute hospital and oncology assets to Ímpar Serviços Hospitalares S.A. ("Ímpar"), a hospital and oncology company belonging to DASA, thus making Ímpar a joint venture with equal 50% voting capital ownership between Amil and DASA, governance model designed to maintain balanced rights, with 3 representatives of each partner and 3 independent members on the board and decisions mostly taken by a simple majority on the board. Amil will contribute to Ímpar certain hospitals and oncology clinics of the Americas Network through a capital increase. In turn, Ímpar will keep all its operations, except for the hospitals and oncology units located in the Northeast region (Hospital São Domingos, Hospital da Bahia, and AMO), which will be segregated from the transaction perimeter.

As a result of the joint control between DASA and Amil in Ímpar and the applicability of CPC 18 (R2) - Investments in Associates and Joint Ventures and CPC 19 (R2) - Joint Arrangements, after the transaction is completed, DASA will no longer consolidate Ímpar's financial statements, recognizing both the investment and its results under the equity method.

The consummation of the transaction is subject to certain customary conditions in business of this nature, including the completion of the due diligence process, approval from relevant authorities, especially the Administrative Council for Economic Defense (CADE), and consents from third parties. For more information regarding the Association Agreement, see the Material Fact - "Association Agreement in Hospitals" and Notice to the Market - "DASA Presentation", disclosed by the Company on June 14, 2024, and available on the Investor Relations ("IR") website of DASA (www.dasa3.com.br).

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

(b) Advance for Future Capital Increase entered between the Company and its controlling shareholders.

On May 15, 2024, the Board of Directors approved the execution of a Private Agreement for Capital Increase between the Company and its controlling shareholders, through which the controlling shareholders commit to contribute the amount of R\$ 1.5 billion to the Company. The advance for future capital increase aims to provide the Company with resources to meet operational and financial obligations and strengthen the Company's working capital. The amount disbursed on behalf of the Company is intended solely and exclusively, in an irrevocable and unretractable manner, for the future capital increase of DASA, with no other possible destination, in any form, other than its capitalization. Moreover, the amounts contributed will not be subject to update or interest, and through the capitalization of advance for future capital increase through the capital increase, the controlling shareholders will receive new registered, book-entry common shares with no par value, issued by the Company.

The issue price of the common shares to be issued in the future capital increase will be determined based on the volume-weighted average price (VWAP) of the Company's common shares quoted in the 60 trading sessions immediately following either (i) the announcement of any transaction that results in a reduction of the Company's net debt by at least R\$ 2.5 billion or (ii) December 31, 2024.

As a result of the transaction of the Association Agreement, disclosed in Note 2.a, the period of 60 trading sessions started counting as of June 17, 2024 for the calculation of the issue price of the shares of the capital increase through the capitalization of the advance for future capital increase, in accordance with the Material Fact disclosed on May 15, 2024. The amount of R\$ 1.5 billion was received by the Company in the second quarter of 2024.

The Company's shareholders will have preferential rights to subscribe to the new shares to be issued in the capital increase, based on their shareholding positions on the date that the Company will inform them through a Notice to Shareholders to be disclosed upon approval of the capital increase.

(c) Issue of Debentures (21st Issue - Certificates of Real Estate Receivables ("CRIs")):

On January 5, 2024, the Board of Directors approved the raising of funds through the Company's 21st issue of simple, unsecured debentures, not convertible into shares, in up to 5 series, totaling up to R\$ 2,137,500,000.00, which may be reduced if there is no exercise or partial exercise of the option for an additional lot of real estate receivables certificates issued by Vert Companhia Securitizadora – CRI, meeting the minimum amount corresponding to R\$ 1,710,000,000.00, which were underwritten exclusively by the debenture holder to make up the backing of the CRI. The net funds obtained and raised by the Company with the issue of the debentures are used by the Company, directly or through its subsidiaries, to pay expenses and costs not yet incurred by the Company or its subsidiaries, directly related to the payment of rents for certain properties and/or real estate projects described within the scope of the offer, meeting the form of use of the funds and the indicative schedule for the use of the funds described in the operation. The operation was completed on January 31, 2024, with a volume of R\$ 1.7 billion, with interest accrued at the Interbank Deposit Certificate ("CDI")+2.12% p.a. and the last series of the offer maturing on January 15, 2034.

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

(d) Discontinuity of foreign operations

The DASA Group is in the process of a review of its business portfolio, seeking to improve the synergies of its operations. Management focus on efficiency of main business units and reduced leverage are the expected benefits.

Thus, on November 6, 2023, it decided to close the operations of the subsidiaries Optiren S.A. ("Optiren") and Nobeloy S.A. ("Nobeloy"), Uruguayan operations. In January 2024, the Company also decided to close the operations of Genia S.A. ("Genia Argentina"), Genia Colômbia SAS ("Genia Colombia"), and Genia Chile SPA ("Genia Chile"). The full closure of these operations is expected to take place during 2024.

Thus, despite not having yet completed all the conditions precedent for their conclusion, on June 30, 2024, the Company classified these businesses as discontinued operations. The information on the balance sheet and statement of income from discontinued operations is presented in Note 27.

(e) Exercise of the call option of Instituto de Hematologia de S.J.R Preto Ltda ("Hemat")

On December 18, 2020, DASA and Hemat's shareholders (jointly, "Parties") signed the Shareholders' Agreement, aiming to regulate the rights and obligations of the Parties, including the form of Hemat's management, in which DASA currently holds 80% of the shares.

On February 6, 2024, the Parties entered into an out-of-court settlement agreement defining the sale and transfer of all the shares (20%) held by Hemat's minority shareholders to DASA, which became the sole shareholder and owner of Hemat. The transaction amounted to R\$ 3.2 million.

(f) Purchase of the remaining shares of DB Genética Serviços Laboratoriais Ltda. ("DB Genera").

As of February 1, 2019, DASA and partners of DB Genera entered into a Share Purchase and Sale Agreement and Other Covenants, whereby DASA acquired 75% of the shares representing the DB Genera's share capital.

On April 3, 2024, the shareholders entered into an out-of-court settlement agreement defining the sale and transfer of all the shares (25%) to DASA, which became the sole shareholder and owner of DB Genera. The transaction amounted to R\$ 27.8 million.

(g) Merger of Laboratório de Pesquisas Clínicas e Bromatológicas Ltda ("Laboratório Biomédico")

To streamline the Company's corporate structure by rationalizing costs, the Company carried out the merger of Laboratório Biomédico on April 30, 2024.

The Company emphasizes (a) the inapplicability of Article 264 of Law 6404/76, since there will be no replacement of ownership interest between the shareholders of the Company and Laboratório Biomédico, and (b) there will be no right of withdrawal for the Company's shareholders due to the merger.

(h) Novo Mercado Free Float Waiver

On February 22, 2024, DASA informed the market of the B3's response to the Company's request for exceptional treatment to comply with the minimum percentage of outstanding shares established in the article 10 of the B3 Novo Mercado regulations. The Company must keep shares representing at least 19.31% of the share capital in free circulation until the free-float replacement, which is expected to occur by February 19, 2025.

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

3 Basis of preparation

3.1 Statement of conformity (with Accounting Pronouncements Committee ("CPC") standards and International Financial Reporting Standards ("IFRS"))

The Company's individual parent company and consolidated interim financial information as at and for the period ended June 30, 2024, was prepared in accordance with CPC 21 (R1) (Interim Financial Reporting) and International Accounting Standard IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), and in a manner consistent with CVM regulations for the presentation of Quarterly Information.

This individual parent company and consolidated interim financial information presents notes with material information explaining changes in DASA Group's financial position and performance since its last individual parent company and consolidated annual financial statements.

The notes on suppliers, taxes payable, and impairment testing (intangible assets) are not being presented in the interim financial information as they do not present unusual balances and/or transactions for the period. Therefore, this individual parent company and consolidated financial information should be read together with Company's individual parent company and consolidated financial statements as at and for the year ended December 31, 2023, issued on March 27, 2024.

Disclosures are limited to all information of significance to the financial statements, being consistent with that used by management in the performance of its duties.

The quarterly information is prepared in Brazilian reais ("R\$"), the company's functional currency, and presented in thousands of reais, unless otherwise indicated.

The issue of this individual parent company and consolidated interim financial information was authorized by the Board of Directors at meeting held on August 14, 2024.

3.2 Statement of value added

The presentation of the individual parent company and consolidated statement of value added is required by Brazilian corporate law and the accounting practices adopted in Brazil applicable to publicly-held companies.

The Statement of Value Added was prepared in accordance with the criteria defined in Technical Pronouncement CPC 09 - Statement of Value Added. The IFRS do not require the presentation of this statement. For IFRS purposes, this statement is presented as supplementary information, and not as part of the required set of the individual parent company and consolidated quarterly information.

3.3 Use of estimates and judgments

The preparation of this interim financial information, Management used judgments and estimates that affect the application of DASA Group's accounting policies, and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and judgments are constantly assessed and are based on prior experience and other factors, including expected future events considered reasonable in the circumstances. Reviews of estimates are recognized on a prospective basis.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Uncertainties on assumptions and estimates

DASA Group makes assumptions based on estimates of the future. By definition, the resulting accounting estimates seldom equal their respective actual profit (loss). Information on uncertainties as to assumptions and estimates as of June 30, 2024, that pose a high risk of resulting in a material adjustment in book balances of assets and liabilities are disclosed in the following notes:

- Note 7 - analysis of expected losses from doubtful accounts and variable consideration. The Company and its subsidiaries apply the calculation approach based on expected credit losses at each reporting date. The provision is determined based on the historical experience of credit losses of each of the subsidiaries, recorded in each group of the aging list of accounts receivable, and adjustments for specific prospective factors for defaulters and the economic environment. Based on historical data from recent years, the statistical provisioning model for expected loss from variable consideration (disallowances) was revisited.
- Note 10 – review of the useful life of intangible assets and impairment test of intangible assets and goodwill. Management annually calculates the impairment test for the goodwill balances arising from the expectation of future profitability of acquired companies and brands, including the intangible assets of these cash-generating units. This is an area that requires the use of judgment by the Management in determining future estimates of the ability to generate future cash flows discounted at a discount rate in the cash-generating units (CGUs). Cash flows are derived from the most recent budget projections approved by Management. The projections consider market expectations for operations, use of judgments related to the income growth rate and perpetuity, estimates of future investments and working capital.
- Note 15 - recognition and measurement of provision for tax, social security, labor and civil claims, main assumptions on the probability and volume of outflows. The Company and its subsidiaries are parties to several ongoing lawsuits as of the quarterly information date. The procedure used by Management to prepare the accounting estimates considers the legal advice of specialists in the area, the status of the proceedings, the situation and the level of judgment of each specific case.
- Note 18 - Income recognition: estimate of expected variable considerations (disallowances). Impairment analysis rules apply to receivables, especially for accounts receivable from healthcare operators. In this area, a high degree of judgment is applied to determine the level of uncertainty associated with the realization of the estimated contractual flows of the assets. This judgment includes maturity history, partnership and counterparty relationship history, and other relevant factors that may affect the constitution of impairment losses.
- Note 22 – Recognition of deferred tax assets: availability of future taxable income against which tax losses may be used. Deferred tax assets are recognized to the extent it is probable that future taxable income will be available. This is an area that requires the use of judgment by the Management in determining future estimates regarding the ability to generate future taxable profits, based on projections of future profit (loss), prepared and based on internal assumptions and future economic scenarios that may have changes.

Fair value measurement

Several accounting policies and disclosures require the measurement of fair value, for financial and non-financial assets and liabilities.

DASA Group has established a control structure for measuring fair values for significant fair value measurements. This includes the responsibility of reviewing all significant fair value measurements, including Level 3 fair values, and report to the Financial Executive Board and Senior Management of DASA Group.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

When third-party information, such as brokerage firms' quotes or market prices, are used to measure fair value, management assesses the evidence to assure the conclusion is consistent with CPC / IFRS requirements, including the fair value hierarchy.

When measuring fair value of an asset or liability, the DASA Group uses observable data as far as possible. Fair values are classified at different levels according to hierarchy based on information (inputs) used in valuation techniques as presented in Note 24 - Financial instruments.

3.4 Basis of measurement

The interim financial information was prepared based on the historical cost, except for the following items recognized in the balance sheets:

- Note 14 - Payable - acquisition of subsidiaries;
- Note 16 - Liabilities for share-based payment transactions settled in cash; and
- Note 24 - Financial instruments measured at fair value through profit or loss.

4 Significant and material accounting policies

DASA Group declares that the accounting practices and policies (which include the principles of measurement, recognition and valuation of assets and liabilities), in addition to the main accounting judgments and sources of uncertainty about estimates adopted in the preparation of this interim financial information, are consistent with those adopted and disclosed in Note 4 of the annual financial statements for the year ended December 31, 2023, published on March 27, 2024.

5 Cash and cash equivalents

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Cash and banks	44,119	116,423	677,725	438,908
Repurchase and resale agreements and CDB's (a)	1,827,086	405,017	2,194,976	1,146,286
	1,871,205	521,440	2,872,701	1,585,194

(a) Repurchase and resale commitments and CDBs (Bank deposit certificates) are remunerated, on average, at a rate of 96.7% of the CDI on June 30, 2024 (96.0% as of December 31, 2023). They have immediate liquidity and are not subject to restrictions or penalties of any kind, which allows its use according to the DASA Group's needs.

6 Securities

	Parent company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Financial bill operations (a)	84,036	79,561	113,721	79,561
Repurchase and resale commitments abroad (b)	-	-	-	24,254
	84,036	79,561	113,721	103,815

(a) LF operations bear interest at 107.5% of the CDI rate, mature in 2025 and can be redeemed on the secondary market before maturity.

(b) Repurchase operations abroad were remunerated on average at 100% of the BADLAR interest rate (benchmark interest rate in Argentina).

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

7 Trade accounts receivable

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Trade accounts receivable:				
Domestic (a)	1,160,533	995,971	5,104,419	4,332,855
Foreign	-	-	65,973	31,475
Related parties (Note 25.a)	88,095	67,484	-	-
	1,248,628	1,063,455	5,170,392	4,364,330
Expected losses from doubtful accounts	(31,276)	(29,732)	(163,482)	(151,407)
Expected losses from variable consideration (disallowances)	(27,642)	(20,672)	(262,699)	(220,343)
Expected losses on doubtful accounts and expected loss from variable consideration (disallowance)	(58,918)	(50,404)	(426,181)	(371,750)
Total trade accounts receivable, net	1,189,710	1,013,051	4,744,211	3,992,580
Current	1,168,647	1,000,860	4,717,061	3,976,643
Non-current	21,063	12,191	27,150	15,937

(a) In June 2024, the Company had prepaid receivables without co-obligation with a financial institution amounting to R\$ 300,541 (R\$ 455,180 in December 2023) and credit card receivables with the respective credit card companies amounting to R\$ 129,909 (R\$ 122,177 in December 2023).

The fair values of trade accounts receivable are close to the book values, mainly due to the high turnover.

An analysis of the aging of trade receivables not yet due is as below:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
To be billed	366,720	274,449	2,036,802	1,653,258
Not yet due	583,373	493,468	2,253,632	2,370,456
Overdue (days):				
≤90	121,668	109,749	372,778	151,570
91–120	17,586	22,832	52,091	26,634
121–180	21,244	31,206	103,972	28,235
181–360	60,183	76,645	164,616	71,411
>360	77,854	55,106	186,501	62,766
	1,248,628	1,063,455	5,170,392	4,364,330

DASA Group developed a methodology for assigning ratings to its clients, considering the histories of receipts and classifying them into two groups: Rating A - clients with a low risk of default, supported by the collection history, and rating B – with the higher degree or risk of default and which considers methodology and more conservative percentages of provisions, according to maturity ranges shown in the aging list.

Changes in expected losses from doubtful accounts ("PECLD"):

	Parent Company	Consolidated
Balance at December 31, 2022	(20,390)	(150,219)
Provision for PECLD (estimated losses on doubtful accounts)	(9,450)	(43,164)
Reversal for PECLD (estimated losses on doubtful accounts)	214	17,027
Balance at June 30, 2023	(29,626)	(176,356)
Balance at December 31, 2023	(29,732)	(151,407)
Provision for PECLD (estimated losses on doubtful accounts)	(4,781)	(35,960)
Reversal for PECLD (estimated losses on doubtful accounts)	3,237	23,885
Balance at June 30, 2024	(31,276)	(163,482)

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

Changes in expected losses from variable consideration (disallowances):

	Parent Company	Consolidated
Balance at December 31, 2022	(41,760)	(72,119)
Provision for disallowance	(3,198)	(11,678)
Reversal of disallowances	9,618	18,210
Balance at June 30, 2023	(35,340)	(65,587)
Balance at December 31, 2023	(20,672)	(220,343)
Provision for disallowance	(8,005)	(43,285)
Reversal of disallowances	1,035	929
Balance at June 30, 2024	(27,642)	(262,699)

8 Investments

8.1 Information about investments (Parent Company)

The breakdown of investments is presented below:

Parent Company	06/30/2024	12/31/2023
Investments in subsidiaries		
Hospitals and oncology (BU1)	7,903,688	7,743,514
Diagnoses and care coordination ("BU2")	787,456	830,509
Diagnoses - International Operations ("BU2")	223,644	100,367
Investments in subsidiaries (Note 8.3)	8,914,788	8,674,390
Goodwill in the acquisition of interest		
Diagnoses and care coordination ("BU2")	1,084,720	1,087,977
Diagnoses - International Operations ("BU2")	25,784	25,613
Goodwill in the acquisition of interest	1,110,504	1,113,590
Intangible assets from acquisition of interest	496,813	496,309
Other investments	2,986	2,988
Total investments	10,525,091	10,287,277

For information by business segment (BU1 and BU2), see Note 23.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

8.2 Information about interest in direct subsidiaries

The chart below presents a summary of the direct subsidiaries' financial information. This information reflects the percentage of interest held by the Company.

Companies	Segment	Period ended June 30, 2024				Year ended December 31, 2023			
		Ownership interest percentage in paid-up capital	Paid-up share capital	Shareholders' equity (Negative shareholders' equity) proportional to the number of shares held	Profit (loss) from direct subsidiaries	Ownership interest percentage in paid-up capital	Paid-up share capital	Shareholders' equity (Negative shareholders' equity) proportional to the number of shares held	Profit (loss) from direct subsidiaries for the period ended June 30, 2023
Aliança Biotecnologia Ltda.	BU2	99.99%	1,462	231	(6)	99.99%	1,462	237	(23)
Allbrokers Brasil Corretora de Seguros Ltda.	BU2	100.00%	236,054	225,278	(13,598)	100.00%	236,054	226,526	(14,389)
Centro de Tomografia por Computador Ltda.	BU2	100.00%	-	-	(1,030)	100.00%	150	15,081	3,297
Cientificalab Prodrodutos Laboratoriais e Sistemas Ltda.	BU2	99.99%	125,177	197,847	17,047	99.99%	125,177	180,800	(19,901)
CPCLIN – Centro de Pesquisas Clínicas Ltda.	BU2	80.00%	1	4,727	3,283	80.00%	1	1,444	357
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	BU2	70.00%	1,080	3,302	258	70.00%	1,080	3,044	883
DASA Real Estate	BU2	99.99%	25,667	30,491	1,268	99.99%	25,667	29,223	1,493
DB Genética Serviços Laboratoriais Ltda.	BU2	100.00%	10	(65,170)	(5,671)	75.00%	10	(44,666)	(8,329)
Diagnóstico Maipú por Imágenes S.A.	BU2	100.00%	3,448	213,032	25,827	100.00%	1,784	84,784	11,852
Fernando Henriques Pinto Junior & CIA Ltda.	BU2	90.00%	51	(8,004)	(709)	90.00%	51	(7,295)	(1,582)
Genia S.A. (c)	BU2	100.00%	1,844	(8,219)	286	100.00%	1,075	(5,443)	(3,508)
Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda.	BU2	100.00%	44,770	1,979	(8,178)	100.00%	44,770	1,707	(5,963)
Ímpar Serviços Hospitalares S.A.	BU1	100.00%	7,249,875	7,903,688	(170,828)	100.00%	7,235,824	7,743,514	(82,219)
Instituto de Hematologia de S.J.R. Preto Ltda.	BU2	100.00%	3,600	(7,216)	(2,771)	80.00%	3,600	(4,352)	(1,986)
Itulab Laboratório de Análises Clín. de Itu Ltda.	BU2	99.99%	5,803	7,423	292	99.99%	5,803	7,131	(82)
Laboratório Bioclínico MS Ltda.	BU2	100.00%	5	1,326	(2,561)	100.00%	5	3,387	1,849
Laboratório Chromatox Ltda.	BU2	100.00%	3,366	19,189	(1,866)	100.00%	3,366	21,055	4,333
Laboratório Deliberato de Análises Clínicas Ltda.	BU2	99.99%	6,800	12,952	(191)	99.99%	6,800	13,143	543
Laboratório Médico Santa Luzia S.A. (a)	-	-	-	-	-	-	-	-	11,645
Laboratório Nobel S.A.	BU2	100.00%	15,863	19,919	(10,856)	100.00%	15,864	27,425	(9,064)
Laboratório de Pesquisas Clínicas e Bromatológicas Ltda. (b)	BU2	100.00%	-	-	200	100.00%	11,058	8,414	-
Maringá Medicina Nuclear Ltda.	BU2	99.99%	15,600	18,972	(3,208)	99.99%	15,600	21,830	(2,570)
MO Holding S.A.	BU2	100.00%	32,378	3,810	(1)	100.00%	32,378	3,811	(6,178)
Mantris Gestão em Saúde Corporativa Ltda	BU2	100.00%	77,845	29,509	(17,227)	100.00%	77,845	35,736	-
Nobeloy S.A. (c)	BU2	100.00%	13,625	2,039	(120)	100.00%	12,404	7,997	(3,867)
Optiren S.A. (c)	BU2	100.00%	5,269	8,573	171	100.00%	4,588	7,586	(4,348)
Patologia Clínica Dr. Geraldo Lustosa Cabral Ltda.	BU2	100.00%	3,400	16,025	1,867	100.00%	3,400	12,158	2,766
Previlab Análises Clínicas Ltda.	BU2	99.56%	29,613	56,315	10,334	99.56%	29,613	45,981	4,209
Ruggeri & Piva Ltda.	BU2	99.99%	7,461	5,856	470	99.99%	7,461	5,386	(1,763)
SALL Participações S.A.	BU2	100.00%	32,000	33,625	(7,243)	100.00%	32,000	40,868	3,310
Salomão e Zoppi Serviços Médicos e Participações S.A.	BU2	100.00%	130,213	51,811	(19,672)	100.00%	130,213	71,483	(19,092)
Santa Celina Participações S.A.	BU2	100.00%	121,439	(46,239)	(36,387)	100.00%	121,439	(9,852)	(27,721)
Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda.	BU2	99.99%	3,372	4,334	47	99.99%	3,372	2,887	(416)
São Marcos – Saúde e Medicina Diagnóstica S.A.	BU2	100.00%	62,600	35,311	(18,487)	100.00%	62,600	47,298	(23,230)
Valeclin Laboratório de Análises Clínicas Ltda.	BU2	100.00%	11,100	7,224	(11,380)	100.00%	11,100	4,454	(7,547)
			8,270,791	8,779,940	(270,640)		8,263,614	8,602,782	(197,241)

(a) Company merged in 2023.

(b) The company became a direct subsidiary of DASA after the merger of Laboratório Médico Santa Luzia. S.A.

(c) Companies in discontinued operations (see Note 27).

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

8.3 Changes in investments in subsidiaries / Provision for unsecured liabilities of subsidiaries.

Changes in investments in subsidiaries are as follows:

Investments on June 30, 2024	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations ("BU2")	Total
Balance at December 31, 2023	7,743,514	830,509	100,367	8,674,390
Advance for future capital increase	317,000	60,050	2,114	379,164
Merger of subsidiaries	-	(8,287)	-	(8,287)
Transfer of subsidiary between reportable segments (b)	14,051	(14,051)	-	-
Equity valuation adjustment (a)	(49)	(327)	95,285	94,909
Equity in results of subsidiaries	(170,828)	(80,438)	25,878	(225,388)
Balance at June 30, 2024	7,903,688	787,456	223,644	8,914,788

Provision for unsecured liabilities in subsidiaries on June 30, 2024	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations ("BU2")	Total
Balance at December 31, 2023	-	(66,165)	(5,443)	(71,608)
Advance for future capital increase	-	1,000	-	1,000
Acquisition of non-controlling interest.	-	(15,926)	-	(15,926)
Equity valuation adjustment (a)	-	-	(3,062)	(3,062)
Equity in results of subsidiaries	-	(45,538)	286	(45,252)
Balance at June 30, 2024	-	(126,629)	(8,219)	(134,848)

Shareholders' equity of direct subsidiaries	7,903,688	660,827	215,425	8,779,940
--	------------------	----------------	----------------	------------------

Investments on June 30, 2023	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations ("BU2")	Total
Balance at December 31, 2022	7,341,849	987,403	207,691	8,536,943
Advance for future capital increase	630,000	58,900	-	688,900
Change in shareholders' equity - acquisition of subsidiaries	-	(14,147)	-	(14,147)
Equity valuation adjustment (a)	(3,489)	2,085	(11,070)	(12,474)
Transfer between investments and provision for losses in subsidiaries	-	1,035	43	1,078
Equity in results of subsidiaries	(82,218)	(105,241)	129	(187,330)
Balance at June 30, 2023	7,886,142	930,035	196,793	9,012,970

Provision for unsecured liabilities in subsidiaries on June 30, 2023	Hospitals and oncology (BU1)	Diagnoses and care coordination ("BU2")	Diagnoses - International Operations ("BU2")	Total
Balance at December 31, 2022	-	(35,164)	-	(35,164)
Transfer between investments and provision for losses in subsidiaries	-	(1,035)	(43)	(1,078)
Equity in results of subsidiaries	-	(9,911)	-	(9,911)
Balance at June 30, 2023	-	(46,110)	(43)	(46,153)

Shareholders' equity of direct subsidiaries	7,886,142	883,925	196,750	8,966,817
--	------------------	----------------	----------------	------------------

(a) Asset valuation adjustments include hyperinflationary accounting adjustment and balance sheet conversion, among others.

(b) After the corporate restructuring, the subsidiary Centro de Tomografia por Computador Ltda. is no longer allocated as BU2 and is currently consolidated in BU1.

For information by business segment (BU1 and BU2), see Note 23.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

9 Property and equipment

The breakdown of property and equipment is as follows:

		Parent Company			
		06/30/2024		12/31/2023	
	Useful life (years)	Cost	Accumulated depreciation	Net	Net
Properties	25	8,304	(1,865)	6,439	6,602
Leasehold improvements	10	1,037,229	(788,246)	248,983	265,237
Improvements to own properties	10	4,066	(4,052)	14	24
Machinery and equipment	10	1,535,523	(1,099,801)	435,722	485,437
Furniture and fixtures	10	136,586	(102,170)	34,416	37,215
Facilities	10	231,231	(138,600)	92,631	99,088
IT equipment	5	360,072	(276,052)	84,020	101,682
Vehicles	5	2,254	(2,254)	-	-
Land	-	180	-	180	180
Construction in progress	-	97,300	-	97,300	90,534
Impairment	-	(983)	-	(983)	(983)
		3,411,762	(2,413,040)	998,722	1,085,016

		Consolidated			
		06/30/2024		12/31/2023	
	Useful life (years)	Cost	Accumulated depreciation	Net	Net
Properties	25	614,584	(127,621)	486,963	482,252
Leasehold improvements	10	2,948,969	(1,477,022)	1,471,947	1,495,047
Improvements to own properties	10	4,436	(4,075)	361	371
Machinery and equipment	10	3,176,747	(2,075,495)	1,101,252	1,197,215
Furniture and fixtures	10	311,017	(213,291)	97,726	102,035
Facilities	10	399,133	(195,111)	204,022	214,747
IT equipment	5	638,542	(448,615)	189,927	211,112
Vehicles	5	5,721	(5,248)	473	172
Land	-	91,673	-	91,673	91,673
Construction in progress	-	256,954	-	256,954	216,633
Impairment	-	(5,509)	-	(5,509)	(6,383)
		8,442,267	(4,546,478)	3,895,789	4,004,874

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Changes in property and equipment are as follows:

Parent Company

	Balance at 12/31/2023	Addition (b)	Addition - merger (a)	Write-off	Transfers	Depreciation	Balance at 06/30/2024
Properties	6,602	-	-	-	-	(163)	6,439
Leasehold improvements	265,237	-	-	-	9,669	(25,923)	248,983
Improvements to own properties	24	-	-	-	-	(10)	14
Machinery and equipment	485,437	-	3	(181)	8,731	(58,268)	435,722
Furniture and fixtures	37,215	-	17	(6)	1,631	(4,441)	34,416
Facilities	99,088	-	23	-	1,912	(8,392)	92,631
IT equipment	101,682	-	3	(13)	2,452	(20,104)	84,020
Land	180	-	-	-	-	-	180
Construction in progress	90,534	79,448	-	-	(72,682)	-	97,300
Impairment	(983)	-	-	-	-	-	(983)
	1,085,016	79,448	46	(200)	(48,287)	(117,301)	998,722

	Balance at 12/31/2022	Addition (b)	Write-off	Transfers	Depreciation	Balance at 06/30/2023
Properties	6,931	-	-	-	(164)	6,767
Leasehold improvements	315,306	-	(576)	9,860	(33,826)	290,764
Improvements to own properties	239	-	-	-	(201)	38
Machinery and equipment	573,832	-	(230)	23,525	(65,377)	531,750
Furniture and fixtures	44,329	-	(33)	685	(4,574)	40,407
Facilities	110,393	-	(144)	2,621	(8,484)	104,386
IT equipment	131,171	-	(30)	6,334	(20,841)	116,634
Vehicles	26	-	-	-	(14)	12
Land	180	-	-	-	-	180
Construction in progress	5,853	47,783	-	(43,025)	-	10,611
Impairment	(4,817)	-	-	-	-	(4,817)
	1,183,443	47,783	(1,013)	-	(133,481)	1,096,732

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Consolidated

	Balance at 12/31/2023	Additions (b)	Write-offs	Net exchange-rate changes (c)	Net inflation (d)	Transfers	Depreciation	Balance at 06/30/2024
Properties	482,252	-	-	1,607	11,429	-	(8,325)	486,963
Leasehold improvements	1,495,047	1,965	(1,115)	4,542	30,765	10,711	(69,968)	1,471,947
Improvements to own properties	371	-	-	-	-	-	(10)	361
Machinery and equipment	1,197,215	8,687	(778)	1,655	4,347	8,773	(118,647)	1,101,252
Furniture and fixtures	102,035	1,892	(86)	170	2,142	1,631	(10,058)	97,726
Facilities	214,747	619	-	48	217	1,938	(13,547)	204,022
IT equipment	211,112	2,100	-	432	6,458	2,466	(32,641)	189,927
Vehicles	172	-	-	8	390	-	(97)	473
Land	91,673	-	-	-	-	-	-	91,673
Construction in progress	216,633	115,463	-	-	-	(75,142)	-	256,954
Impairment	(6,383)	-	874	-	-	-	-	(5,509)
	4,004,874	130,726	(1,105)	8,462	55,748	(49,623)	(253,293)	3,895,789

	Balance at 12/31/2022	Additions (b)	Write-offs	Net exchange-rate changes (c)	Net inflation (d)	Transfers	Depreciation	Balance at 06/30/2023
Properties	485,201	-	(127)	(9,382)	8,579	-	(6,532)	477,739
Leasehold improvements	1,221,539	2,007	(557)	(29,745)	22,819	160,176	(63,715)	1,312,524
Improvements to own properties	261	-	(5)	654	(532)	4,141	(4,359)	160
Machinery and equipment	1,322,076	25,694	(727)	(9,168)	7,255	38,977	(125,448)	1,258,659
Furniture and fixtures	123,307	3,146	(74)	(1,012)	450	674	(10,465)	116,026
Facilities	101,505	7,850	(43)	(737)	(413)	52,376	(10,044)	150,494
IT equipment	258,168	7,299	239	(1,088)	1,171	6,729	(32,212)	240,306
Vehicles	437	81	-	(8)	(8)	1	(189)	314
Library	1	-	-	-	-	-	-	1
Land	89,707	1,966	-	-	-	-	-	91,673
Construction in progress	544,270	108,845	(47)	(33)	-	(263,035)	-	390,000
Impairment	(5,150)	-	-	-	-	-	-	(5,150)
	4,141,322	156,888	(1,341)	(50,519)	39,321	39	(252,964)	4,032,746

- (a) In the parent company, the balance refers to the mergers of subsidiaries that took place during the period.
- (b) Mainly ongoing investments in appliances, equipment, and leasehold improvements. Additions include the amounts of R\$ 12,051 in the parent company and R\$ 16,369 in the consolidated with no cash effects in the period, since they are installment payments (R\$ 13,557 in the parent company and R\$ 14,041 in the consolidated as of June 30, 2023).
- (c) In the consolidation of property and equipment of foreign operations, the balance is translated into Reais at the exchange rate on the base date of the quarterly information.
- (d) Application of CPC 42 / IAS 29 - Financial Reporting in Hyperinflationary Economies. Updates are made by applying a general price index in the period between the date of acquisition/occurrence up to the base date of quarterly information.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The accumulated depreciation additions presented in changes in property and equipment were partly recorded in general and administrative expenses and partially recorded in costs of services rendered. This allocation is linked to the final use of each asset.

For the period ended June 30, 2024, the Management concluded that there are no indications of impairment losses in the property and equipment which result in the need of additional provision to balances that are recorded in the individual parent company and consolidated quarterly information.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

10 Intangible assets

The breakdown of intangible assets is as follows:

		Parent Company			
				06/30/2024	12/31/2023
	Useful life in years	Cost	Accumulated amortization	Net	Net
Goodwill related to interest acquisitions					
Acquisition of interest - Goodwill		2,439,790	(281,917)	2,157,873	2,157,873
		2,439,790	(281,917)	2,157,873	2,157,873
Intangible asset from acquisition of interest:					
Brands	30	328,782	(130,012)	198,770	204,224
Relationship with clients	20	81,029	(46,411)	34,618	36,158
Software	5	-	7,680	7,680	7,680
Non-compete agreement		702	(702)	-	-
		410,513	(169,445)	241,068	248,062
Other intangible assets:					
IT systems	5	1,669,194	(1,070,510)	598,684	677,273
Commercial rights-of-use	5	5,488	(5,483)	5	363
Patents	33	96	(78)	18	20
Client exclusivity contracts	5	23,368	(19,062)	4,306	150,016
Goodwill	5	1,243	(621)	622	690
Intangible assets in progress		1,267	-	1,267	1,267
		1,700,656	(1,095,754)	604,902	829,629
		4,550,959	(1,547,116)	3,003,843	3,235,564

		Consolidated			
				06/30/2024	12/31/2023
	Useful life in years	Cost	Accumulated amortization	Net	Net
Goodwill related to interest acquisitions					
Acquisition of interest - Goodwill		9,135,007	(193,697)	8,941,310	8,944,923
		9,135,007	(193,697)	8,941,310	8,944,923
Intangible asset from acquisition of interest:					
Brands	30	767,034	(199,604)	567,430	574,823
Relationship with clients	20	277,949	(63,156)	214,793	198,456
Appreciation of assets	5	339	(130)	209	339
Non-compete agreement	7	25,058	(18,771)	6,287	8,908
Software	5	21,237	4,243	25,480	28,918
		1,091,617	(277,418)	814,199	811,444
Other intangible assets:					
IT systems	5	1,942,798	(1,223,228)	719,570	806,311
Commercial rights-of-use	5	5,517	(5,483)	34	392
Patents	33	1,883	(737)	1,146	1,480
Client exclusivity contracts	5	46,713	(38,177)	8,536	156,554
Goodwill	5	6,666	(2,774)	3,892	4,503
Intangible assets in progress		10,302	-	10,302	9,350
		2,013,879	(1,270,399)	743,480	978,590
		12,240,503	(1,741,514)	10,498,989	10,734,957

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The changes in intangible assets are presented below:

	Parent Company					
	Balance at 12/31/2023	Additions (a)	Write-off	Transfers (c)	Amortization	06/30/2024
Goodwill related to interest acquisitions						
Acquisition of interest - Goodwill	2,157,873	-	-	-	-	2,157,873
Intangible asset from acquisition of interest:						
Brands	204,224	-	(209)	-	(5,245)	198,770
Relationship with clients	36,158	-	(41)	-	(1,499)	34,618
Software	7,680	-	-	-	-	7,680
	248,062	-	(250)	-	(6,744)	241,068
Other intangible assets:						
IT systems	677,273	-	-	49,428	(128,016)	598,685
Commercial rights-of-use	363	-	-	-	(359)	4
Trademarks and patents	20	-	-	-	(1)	19
Client exclusivity contract (d)	150,016	-	(137,534)	-	(8,176)	4,306
Goodwill	690	-	-	-	(69)	621
Intangible assets in progress	1,267	1,141	-	(1,141)	-	1,267
	829,629	1,141	(137,534)	48,287	(136,621)	604,902
	3,235,564	1,141	(137,784)	48,287	(143,365)	3,003,843

	Balance at 12/31/2022	Additions (a)	Merger of subsidiaries	Write-offs	Transfers (c)	Amortization	Balance at 06/30/2023
Goodwill related to interest acquisitions							
Acquisition of interest - Goodwill	2,055,275	-	92,620	-	-	-	2,147,895
Intangible asset from acquisition of interest:							
Brands	201,974	-	-	-	-	(5,188)	196,786
Relationship with clients	33,930	-	-	-	-	(1,420)	32,510
Appreciation of assets	-	-	-	-	-	-	-
Non-compete agreement	35	-	-	-	-	(35)	-
Software	7,680	-	-	-	-	-	7,680
	2,298,894	-	92,620	-	-	(6,643)	2,384,871
Other intangible assets:							
IT systems	709,491	-	-	-	100,595	(108,674)	701,412
Commercial rights-of-use	1,433	-	-	(157)	-	(484)	792
Trademarks and patents	23	-	-	-	-	(2)	21
Client exclusivity contracts	7,586	156,684	-	-	-	(5,344)	158,926
Goodwill	828	-	-	-	-	(69)	759
Intangible assets in progress	1,267	100,595	-	-	(100,595)	-	1,267
	720,628	257,279	-	(157)	-	(114,573)	863,177
	3,019,522	257,279	92,620	(157)	-	(121,216)	3,248,048

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Consolidated							
	Balance at 12/31/2023	Additions (a)	Write-off	Net exchange- rate changes	Net inflation (b)	Transfers (c)	Amortization	Balance at 06/30/2024
Goodwill related to interest acquisitions								
Acquisition of interest - Goodwill	8,944,923	-	(527)	(3,086)	-	-	-	8,941,310
Intangible asset from acquisition of interest:								
Brands	574,823	18	-	15,761	8,373	-	(31,545)	567,430
Relationship with clients	198,456	-	(41)	36,154	-	-	(19,776)	214,793
Appreciation of assets	339	-	-	-	-	-	(130)	209
Non-compete agreement	8,908	-	-	-	-	-	(2,621)	6,287
Software	28,918	-	-	-	-	-	(3,438)	25,480
	811,444	18	(41)	51,915	8,373	-	(57,510)	814,199
Other intangible assets:								
IT systems	806,311	3,771	-	1,281	3,040	52,448	(147,281)	719,570
Commercial rights-of-use	392	-	-	-	-	-	(358)	34
Trademarks and patents	1,481	-	-	-	-	-	(335)	1,146
Client exclusivity contract (d)	156,554	-	(137,534)	-	-	-	(10,484)	8,536
Goodwill	4,503	-	-	-	-	-	(611)	3,892
Intangible assets in progress	9,350	3,777	-	-	-	(2,825)	-	10,302
	978,591	7,548	(137,534)	1,281	3,040	49,623	(159,069)	743,480
	10,734,958	7,566	(138,102)	50,110	11,413	49,623	(216,579)	10,498,989

	Balance at 12/31/2022	Additions (a)	Write-off	Net exchange- rate changes	Net inflation (b)	Transfers (c)	Amortization	Balance at 06/30/2023
Goodwill related to interest acquisitions								
Acquisition of interest - Goodwill	9,024,261	-	-	(16,837)	-	(54,951)	-	8,952,473
Intangible asset from acquisition of interest:								
Brands	547,919	-	-	(31,407)	13,245	16,932	(19,745)	526,944
Relationship with clients	338,859	-	-	(6,344)	-	18,683	(19,849)	331,349
Non-compete agreement	589	-	-	-	-	-	(1,346)	(757)
Software	16,932	-	-	-	-	18,957	(1,859)	34,030
	904,299	-	-	(37,751)	13,245	54,572	(42,799)	891,566
Other intangible assets:								
IT systems	799,471	20,648	(123)	(2,232)	1,341	106,922	(117,943)	808,084
Commercial rights-of-use	3,957	-	(157)	(1)	-	1	(485)	3,315
Trademarks and patents	465	140	(140)	-	-	-	(4)	461
Client exclusivity contracts	21,745	156,684	-	49	-	-	(7,651)	170,827
Goodwill	5,614	-	-	-	-	-	(537)	5,077
Intangible assets in progress	6,205	106,766	-	-	-	(106,583)	-	6,388
	837,457	284,238	(420)	(2,184)	1,341	340	(126,620)	994,152
	10,766,017	284,238	(420)	(56,772)	14,586	(39)	(169,419)	10,838,191

(a) Mainly investments in systems development and contract with Unimed Rio. Additions include the amounts of R\$ 1,141 in the parent company and R\$ 2,015 in the consolidated with no cash effects in the period, since they are installment payments (R\$ 28,851 in the parent company and R\$ 29,780 in the consolidated as of June 30, 2023).

(b) Application of CPC 42 / IAS 29 - Financial Reporting in Hyperinflationary Economies. Updates are made by applying a general price index in the period between the date of acquisition/occurrence up to the base date of quarterly information.

(c) The expenses incurred, classified as intangible assets in progress during the development period, are transferred to a specific item in the intangible group when they are available for use.

(d) Value related to the write-off of the exclusivity contract with Unimed Rio, after an agreement between the parties involved.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

11 Loans and financing

Modality	Parent company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Working capital (a)	9,461	11,958	116,383	191,775
Leasing (b)	-	-	4	495
	9,461	11,958	116,387	192,270
Current	4,168	4,743	87,520	122,966
Non-current	5,293	7,215	28,867	69,304

Loans and financing have the following collaterals:

- (a) Real estate, surety, assignment of credit receivables, letter of guarantee, mortgage, lien.
- (b) Financed asset.

Changes in loans and financing balances were as follows:

	Parent Company	Consolidated
Balance at December 31, 2022	2,124,403	2,559,398
Interest accrued and exchange rate changes	145,249	160,132
Interest paid	(151,183)	(171,671)
Amortization of principal	(704)	(126,782)
Balance at June 30, 2023	2,117,766	2,421,077
Balance at December 31, 2023	11,958	192,270
Interest accrued	455	7,727
Exchange-rate change	-	6,896
Interest paid	(466)	(10,120)
Amortization of principal	(2,486)	(80,386)
Balance at June 30, 2024	9,461	116,387
Current	4,168	87,520
Non-current	5,293	28,867

Loans classified in non-current liabilities mature as follows:

	06/30/2024		12/31/2023	
	Parent Company	Consolidated	Parent company	Consolidated
01–02 years	2,409	18,536	4,331	45,527
02–03 years	2,884	10,331	2,884	23,777
	5,293	28,867	7,215	69,304

The DASA Group has three loan and financing agreements that have financial leverage covenant clauses. Said contracts total R\$ 4,751 and account for 4.1% of the total amount of loans and financing (consolidated). The company is complying with these contracts, fulfilling all its obligations.

Other bank loan and financing agreements do not have negative covenants.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

12 Right-of-use assets and lease liabilities

DASA Group leases property including service units, diagnosis, warehouses, administrative offices, hospitals and technical operational centers. The terms of the contracts vary between 5 and 10 years and are negotiated individually.

Breakdown of right-of-use assets is as follows:

	Parent Company	Consolidated
Right-of-use assets		
Balance at December 31, 2022	962,194	2,331,903
Additions	29,043	76,492
Remeasurement (b)	19,835	18,949
Amortization	(97,935)	(201,123)
Balance at June 30, 2023	913,138	2,226,222
Balance at December 31, 2023	889,855	2,474,055
Additions	17,895	20,616
Write-off	(18,021)	(28,015)
Remeasurement (b)	72,556	105,670
Amortization	(94,537)	(188,072)
Balance at June 30, 2024	867,748	2,384,254

The changes in lease liabilities are as follows:

	Parent Company	Consolidated
Lease liabilities		
Balance at December 31, 2022	963,899	2,441,808
Additions	29,043	76,492
Interest accrued (a)	44,699	104,108
Payments of principal	(126,355)	(281,532)
Remeasurement (b)	19,835	18,949
Balance at June 30, 2023	931,122	2,359,825
Balance at December 31, 2023	928,001	2,643,191
Additions	17,895	20,616
Write-off	(19,872)	(28,771)
Interest accrued (a)	45,984	158,922
Interest paid	(45,984)	(158,922)
Payments of principal	(94,488)	(157,947)
Remeasurement (b)	72,556	105,670
Balance at June 30, 2024	904,092	2,582,759
Current	227,779	429,095
Non-current	676,313	2,153,664

(a) Interest is recorded under "Financial expenses".

(b) Remeasurement originates from changes in future lease payments resulting from adjustments in monthly amounts by the inflation index of the respective contract and/or effectiveness period of lease agreement.

For the calculation of lease contracts, the discount rate the following average market funding rates were used:

Agreement term	Rate
01–02 years	10.5%
03–04 years	11.9%
05–09 years	10.2%
>10 years	11.1%
Weighted average	10.9%

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The maturity dates of non-current installments are presented below:

	06/30/2024		12/31/2023	
	Parent Company	Consolidated	Parent company	Consolidated
01–02 years	52,543	167,322	148,214	175,940
02–03 years	107,242	341,502	294,761	359,092
03–04 years	104,737	333,525	138,590	350,704
>04 years	411,791	1,311,315	164,241	1,378,857
	676,313	2,153,664	745,806	2,264,593

13 Debentures

Breakdown of debentures is as follows:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Non-convertible debentures	10,960,000	10,150,000	11,060,000	10,350,000
Interest accrued	292,234	205,401	292,908	206,795
Transaction costs	(122,123)	(97,366)	(122,255)	(97,628)
	11,130,111	10,258,035	11,230,653	10,459,167
Current	1,253,565	1,194,698	1,354,107	1,395,830
Non-current	9,876,546	9,063,337	9,876,546	9,063,337

Changes in debenture balances were as follows:

	Parent Company	Consolidated
Balance at December 31, 2022	8,499,835	8,902,701
Interest accrued	616,488	644,389
Interest paid	(603,800)	(632,718)
Amortization of principal	(114,959)	(214,959)
Transaction costs	(609)	(478)
Balance at June 30, 2023	8,396,955	8,698,935
Balance at December 31, 2023	10,258,035	10,459,167
Funding (a)	1,710,000	1,710,000
Interest accrued	636,594	647,800
Inflation adjustment	26,486	26,486
Interest paid	(576,247)	(588,174)
Amortization of principal (b)	(900,000)	(1,000,000)
Transaction costs	(24,757)	(24,626)
Balance at June 30, 2024	11,130,111	11,230,653

- (a) On January 31, 2024, the Company raised R\$ 1.71 billion through the 21st issue of Debentures (see Note 2.c).
(b) On February 6, 2024, the total early redemption of 900,000 (nine hundred thousand) simple debentures, not convertible into shares with real guarantee, in a single series, of the 19th issue of the Company, took place with a nominal unit value of R\$ 1,000 (one thousand reais), amounting to R\$ 900 million.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Debentures classified in non-current liabilities mature as follows:

	Parent Company / Consolidated	
	06/30/2024	12/31/2023
01–02 years	424,787	839,928
02–03 years	2,438,039	2,666,315
03–04 years	3,041,159	3,257,094
>04 years	3,972,561	2,300,000
	9,876,546	9,063,337

Debenture transactions contracted by the Company require compliance with restrictive financial clauses, under penalty of early maturity ("covenants"). Failure to comply with obligations or restrictions for two consecutive quarters may lead to the early maturity of the related debts and default in relation to other contractual obligations (cross-default) of each debenture agreement.

The expected levels are calculated based on the consolidated financial statements and adjusted as provided for in the respective agreements for covenant purposes, as described below:

- 1- Net debt/EBITDA - maximum ratio of 4.00
- 2- EBITDA/Financial profit (loss) - minimum ratio of 1.50

Financial net debt for covenants: being: (i) the sum of all consolidated debts of the Company to individuals and/or legal entities for: (a) loans and financing with third parties; (b) debts arising from issues of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; less (ii) the sum of (a) the amount available in the Company's cash; (b) the net balances of the Company's bank checking accounts; and (c) Company's balances of interest earning bank deposits. For the purposes of calculating this financial ratio, on June 30, 2024, R\$ 2,953 thousand corresponds to the net financial cash for the purposes of the discontinued operations' covenants.

Adjusted EBITDA (Earnings before interest, taxes, depreciation and amortization) for covenants: being a non-accounting measure over the four immediately preceding quarters, reflecting the Company's profit before net financial expenses, income tax and social contribution on income, depreciation, amortization, and expenses with stock option plan. In case of acquisition(s), the EBITDA generated in the period of twelve (12) months immediately preceding the end of each quarter of the calendar year by the acquiree(s) will be considered for the purposes of calculating the Company's EBITDA. Therefore, the Company included, for purposes of calculating this financial index, as of June 30, 2024, -R\$ 509 thousand corresponding to the sum of EBITDA of the acquirees in the last 12 months. For the purposes of calculating this financial ratio, on June 30, 2024, -R\$ 17,497 corresponds to the Adjusted EBITDA for covenant purposes in the last 12 months of discontinued operations.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Financial profit (loss) for covenants

10th Issue: It means the difference between the Company's financial income and financial expenses for the four (4) quarters of the calendar year immediately preceding the quarter of the calendar year then in progress, from which interest on equity should be excluded for the purpose of calculating financial commitments, which are calculated in module if it is negative and, if positive, it will not be considered for calculation. This calculation excludes the interest actually disbursed and/or provisioned due to confession of debt with a private pension entity, as well as exchange and monetary variations on debt and cash and expenses arising from provisions that had no impact on the Company's cash flow, but only accounting records, based on the Company's Consolidated financial statements. For the purposes of calculating this financial ratio, on June 30, 2024, R\$ 4,815 thousand corresponds to the financial profit (loss) for the purposes of covenants (10th issue) of discontinued operations.

Other issues: it means the difference between the financial income and the financial expenses of the Company relating to the 4 (four) quarters of the calendar year immediately prior to the quarter of the calendar year then in progress, relating exclusively to (i) the financial expenses relating to the consolidated debts of the Company before individuals and/or legal entities, limited to (a) loans and financing with third parties; (b) debts arising from issues of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; and (ii) financial income referring to (a) the amount available in the Company's cash; (b) the net balances of the Company's bank checking accounts; and (c) balances of the Company's interest earning bank deposits. For the purposes of calculating this financial ratio, on June 30, 2024, R\$ 1,363 thousand corresponds to the financial profit (loss) for the purposes of covenants (other issues) of discontinued operations.

On June 30, 2024, DASA Group was fully in compliance with contractual conditions.

For the period ended June 30, 2024, the net debt/EBITDA financial covenant ratio was 3.47x, below the limit provided for in the deeds of 4.0x.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

14 Payable - acquisition of subsidiaries

Payable - acquisition of subsidiaries refer to payables to the previous owners for the acquisition of shares or quotas of the acquirees.

Changes in Payable - acquisition of subsidiaries are as follows:

Parent Company

	Not collateralized by interest earning bank deposits	Not collateralized by interest earning bank deposits - International	Collateralized by means of restricted interest earning bank deposits	Contingent consideration	Total
Balance at December 31, 2022	159,370	2,511	22,366	8,335	192,582
Acquisitions	-	-	-	39	39
Inflation adjustment and exchange-rate change	9,415	(192)	1,175	404	10,802
Payments	(6,343)	-	-	(1,555)	(7,898)
Balance at June 30, 2023	162,442	2,319	23,541	7,224	195,526
Balance at December 31, 2023	87,078	44,296	6,475	8,557	146,406
Acquisitions	-	-	-	126	126
Inflation adjustment	2,862	-	253	763	3,878
Exchange-rate change	-	4,666	-	-	4,666
Payments	(21,955)	(22,463)	-	(68)	(44,486)
Balance at June 30, 2024	67,985	26,499	6,728	9,378	110,590
Current					81,101
Non-current					29,489

Consolidated

	Not collateralized by interest earning bank deposits	Not collateralized by interest earning bank deposits - International	Collateralized by means of restricted interest earning bank deposits	Contingent consideration	Total
Balance at December 31, 2022	1,222,113	2,511	22,490	67,478	1,314,592
Acquisitions	-	-	-	39	39
Inflation adjustment and exchange-rate change	80,293	(192)	1,180	404	81,685
Payments	(57,206)	-	-	(1,555)	(58,761)
Balance at June 30, 2023	1,245,200	2,319	23,670	66,366	1,337,555
Balance at December 31, 2023	1,148,347	44,296	6,605	67,700	1,266,948
Acquisitions	7,173	-	-	126	7,299
Inflation adjustment	68,190	-	783	763	69,736
Exchange-rate change	-	4,666	-	-	4,666
Payments	(72,656)	(22,463)	-	(68)	(95,187)
Balance at June 30, 2024	1,151,054	26,499	7,388	68,521	1,253,462
Current					529,706
Non-current					723,756

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The portions classified in non-current liabilities have the following payment schedule:

	06/30/2024		12/31/2023	
	Parent Company	Consolidated	Parent company	Consolidated
01–02 years	27,495	116,495	67,776	183,720
02–03 years	1,994	106,452	-	102,281
03–04 years	-	457,782	-	434,906
04–05 years	-	33,082	-	31,442
>05 years	-	9,945	-	9,453
	29,489	723,756	67,776	761,802

Put and call option - non-controlling shareholders

As part of the agreement to acquire equity interests, put options were issued by the Company or its subsidiaries in favor of the non-controlling shareholders and call options were issued by the sellers in favor of the Company or its subsidiaries, which may result in acquisition by the Company or its subsidiaries of the remaining shares of non-controlling shareholders, in the following Companies: Fernando Henriques Pinto Junior & CIA Ltda. ("Padrão"), CPCLin – Centro de Pesquisa Clínicas Ltda. ("CPCLin") and Nossa Senhora do Carmo Participações ("Grupo Carmo").

Call and put option balances are recorded under other accounts payable and provisions and other credits.

15 Tax, social security, labor and civil provisions, contingencies and judicial deposits.

a) Tax, social security, labor and civil provision and judicial deposits

A provision is made for tax, social security, labor and civil lawsuits when the prognosis is assessed by its legal advisors as a risk of loss.

Some of these provisions have, in whole or in part, judicial deposits related to them.

The table below shows the breakdown of provisions and judicial deposits by type:

	Parent Company				Consolidated			
	06/30/2024		12/31/2023		06/30/2024		12/31/2023	
	Provision	Judicial deposit	Provision	Judicial deposit	Provision	Judicial deposit	Provision	Judicial deposit
Labor and civil	35,393	19,504	45,094	19,101	170,409	73,302	175,775	66,346
Tax and social security claims	92,856	33,051	64,525	40,552	320,171	43,888	283,842	51,814
	128,249	52,555	109,619	59,653	490,580	117,190	459,617	118,160

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Changes in tax, social security, labor and civil provisions were as follows:

	Labor and civil		Tax and social security	
	Parent Company	Consolidated	Parent company	Consolidated
Balance at December 31, 2022	34,041	121,071	91,959	280,178
Addition to provision	35,122	6,079	2,877	2,356
Write-off/Settlement	(26,197)	(34,375)	(19,897)	(21,978)
Restatement (reversal)	9,353	9,908	(13,550)	20,675
Balance at June 30, 2023	52,319	102,683	61,389	281,231
Balance at December 31, 2023	45,094	175,775	64,525	283,842
Addition to provision (Dasa's Management)	5,980	16,810	46,641	52,692
Additions (mergers)	87	-	-	-
Additions (reversals) to the provision with a balancing entry (Former management) (a)	(583)	(5,971)	421	3,989
Use (Dasa's Management)	(9,209)	(12,892)	(16,151)	(17,679)
Update (Reversal) - (Dasa Management)	(5,976)	(3,313)	(2,580)	(2,673)
Balance at June 30, 2024	35,393	170,409	92,856	320,171

(a) The Company, within the contracts for the acquisition of subsidiaries, has agreements on contingent lawsuits where the responsibility for payment/disbursement, in the event of loss of these lawsuits, lies with the former management (former owner). For these lawsuits, the provision is made under "Tax, social security, labor and civil provision" against amounts receivable from former management.

b) Contingent liabilities (possible)

The Company and its subsidiaries are also parties to lawsuits with a possible chance of loss (chance of loss greater than 25% and lower than or equal to 50%) as assessed by their legal advisors. Based on this assessment, no provision has been made in the quarterly information, as summarized below:

Labor and civil contingencies

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Civil lawsuits				
Former management – responsibility of former partner	1,784	3,421	1,099,015	1,082,258
DASA Management	52,969	38,269	377,209	210,692
Labor lawsuits				
Former management – responsibility of former partner	1,593	1,040	61,811	54,540
DASA Management	120,027	102,952	271,398	204,603

In the consolidated, the higher values under DASA Management refer to:

- indemnity lawsuit claiming the existence of acts of administrative misconduct and violation of principles and damages to the public coffers in the engagement of Hospital Maternidade Cristóvão da Gama by Instituto de Previdência de Santo André - IPSA, linked to the term of the former management of the hospital, in the amount of R\$ 325,899 on June 30, 2024 (R\$ 310,909 on December 31, 2023), with 35% under DASA Management; and
- public civil action for administrative misconduct for alleged irregularities in the bidding process for the hiring of Científica Lab Produtos Laboratoriais e Sistemas Ltda. in the amount of R\$ 50,234 on June 30, 2024 (R\$ 49,054 on December 31, 2023).

Contingencies for tax and social security claims

The provision for tax and social security claims correspond to (i) challenges for increases in rates (ii) calculation basis and (iii) unconstitutionality of collectible amounts.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Tax and social security claims				
Former management – responsibility of former partner	15,123	15,279	422,335	408,679
DASA Management	1,256,899	1,194,947	1,383,966	1,316,849

In the consolidated, the higher values under DASA Management refer to:

- ISS lawsuits, which basically discuss the location of clinical analysis service provision, in the amount of R\$ 640,369 on June 30, 2024 (R\$ 593,973 on December 31, 2023)
- billing of PIS/COFINS on revenue and imports in the amount of R\$ 118,553 on June 30, 2024 (R\$ 152,388 on December 31, 2023); and
- income tax and social contribution credits on net income in the amount of R\$ 353,660 (R\$ 347,705 on December 31, 2023).

16 Share-based payment

The company currently offers its executives share-based remuneration plans:

- 2018 Plan – Stock option approved at the Company's Extraordinary General Meeting ("EGM") held on December 21, 2018 ("2018 Plan"): The Company granted participants of the former Stock Option Plan ("2016 Plan") the opportunity to choose, at their sole discretion, to replace the options they held with options under the 2018 Plan. As a result, all participants in the 2016 Plan decided to migrate their options to the 2018 Plan, so that there were no open options left subject to the terms and conditions of the 2016 Plan. However, the migrated options are still open in the 2018 Plan.
- The "2020 Plan – Stock option" for the period from 2020 to 2023 approved at the AGM on November 30, 2020 ("2020 Plan"). On May 10, 2023, the Board of Directors approved the 4th Program of "2020 Plan" and the Company carried out a new grant, whose vesting period will be on December 31, 2026, and the effect is already considered in the changes presented below.

The purpose of these plans is to align the Company's interests with those of shareholders and beneficiaries, attract and retain talent, mitigate agency conflicts, increase the generation of sustainable results and reinforce long-term guidance in decision making by the Company's executives and employees.

The Beneficiaries will be chosen and elected by the Board of Directors, at its sole discretion.

Plans will be managed by the Board of Directors, which may rely on a committee to assist it in this regard, and will have, to the extent permitted by law and by the Company's bylaws, broad powers to take all necessary and appropriate measures for the management of these plans.

The Options that may be granted under the "2020 Plan" may not exceed 28,848,825 of Representative Options, on the date of approval of the "2020 Plan", of approximately 6% (six percent) of the Company's share capital.

In the "2020 Plan", the strike price is defined based on the fair value of the shares on the grant date and it is monetarily adjusted by a CDI index, while the vesting period (service condition) is 4 years. Premiums must be fully exercised at the end of the grace period.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The determination of settlement amounts in "2020 Plan" considers the unit price of the Company's shares on the stock exchange corresponding to the weighted average of the last 30 (thirty) trading sessions immediately prior to the expiration date of the Grace Period in question. The settlement of option for the "2020 Plan" determines the settlement in shares. Notwithstanding the foregoing, the Company may, at its discretion, choose to settle in cash, in part or in full.

The fair value of options is measured using the Black-Scholes method. Expected volatility was based on an assessment of the historical volatility of the share price of similar entities, particularly over the historical period proportional to the expected term.

The table below refers to the number of options issued in each program, still outstanding, at the time of the grant versus the number of remaining options to be settled, considering the period ended June 30, 2024.

Under the 2018 Plan, the following grants were approved:

Year of approval	Number of issued shares	Number of remaining options
2018	4,663,274	487,803
2019	5,215,000	756,163

Under the 2020 Plan, the following grants were approved:

Year of approval	Number of issued shares	Number of remaining options
2020	7,181,250	1,561,454
2021	6,413,500	1,877,210
2022	6,506,500	4,583,250
2023	8,843,375	6,596,250

Provision for share-based payment is as follows:

	Parent company/ Consolidated
Balance at December 31, 2022	567,429
Stock option plan expense	33,788
Payments	(828)
Balance at June 30, 2023	600,389
Balance at December 31, 2023	628,173
Stock option plan expense	7,756
Payments	-
Balance at June 30, 2024	635,929
	06/30/202412/31/2023
Current liabilities	72,03956,075
Non-current liabilities	2,39716,962
Shareholders' equity	561,493555,136
Total in balance sheet (share-based payment)	635,929628,173

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

17 Shareholders' equity**a) Share capital**

As of June 31, 2024, the Company's paid-up and subscribed share capital totals R\$ 18,032,489 (R\$ 18,032,489 as of December 30, 2023), represented by 752,799,844 (752,799,844 as of December 31, 2023) common shares, nominative, book-entry and with no par value, presented in the statement of shareholders' equity of R\$ 17,946,204, net of Costs with issue of shares of R\$ 86,285.

Capital increase is pre-approved for the issue of new shares up to the limit of 1,600,000 (one billion six hundred million) common shares, without need of prior amendments to the statute.

b) Equity valuation adjustment

These are shareholder transactions related to the call and put option of controlling shareholders, the effects of translating balances to the presentation currency for foreign subsidiaries and of hyperinflationary accounting effects for the Argentine subsidiary as detailed in Note 4.

Furthermore, due to the merger of Ímpar into DASA in 2020, the amount of R\$ 9,243,944 was recorded as an equity valuation adjustment, thus reducing DASA's shareholders' equity. For further details on this transaction, see Note 2 "Common control transactions" of the financial statements as of December 31, 2020, issued on March 6, 2021.

c) Treasury shares

As of June 30, 2024, treasury shares total 5,378,193 (5,751,757 as of December 31, 2023) acquired at an average price of R\$ 14.13 per share (R\$ 14.13 as of December 31, 2023), totaling a balance of treasury shares of R\$ 79,376 (R\$ 81,258 as of December 31, 2023).

In a Board of Directors' meeting held on August 12, 2022, a "Repurchase Program" of own shares was approved. The number of shares to be acquired in the buyback program was limited to 14,060,719 common shares issued by the Company, accounting for 19.57% of the shares outstanding in the market, on the approval date, following the limit set forth in Article 9 of CVM Resolution 77. The program ended on February 12, 2024.

d) Dividends and interest on own capital

According to the Company's by-laws, net income for the year is allocated as follows: (i) 5% for formation of legal reserve, until reaches 20% of subscribed share capital; and (ii) at least 25% of the remaining balance adjusted, pursuant to article 202 of Law 6,404/76, for the payment of mandatory dividends.

e) (Basic and diluted) earnings (losses) per share

Basic earnings (losses) per share are calculated by dividing profit (loss) attributable to Company's controlling shareholders by the weighted average number of common shares issued during the period, excluding shares held in treasury.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Calculation of Parent Company's basic profit (loss) per share is as follows:

	06/30/2024	06/30/2023
Loss attributable to Company's (controlling) shareholders	(280,578)	(448,151)
Weighted average value of outstanding common shares (in thousands)	747,218	746,880
Basic loss per share - (in R\$)	<u>(0.37550)</u>	<u>(0.60003)</u>

Diluted earnings (losses) per share is calculated by adjusting to weighted average quantity of outstanding common shares, assuming conversion of all common shares that would possibly provoke dilution. The only dilutable event corresponds to the stock option plan (see Note 16).

Calculation of Parent Company's diluted profit (loss) per share is as follows:

	06/30/2024	06/30/2023
Loss attributable to Company's (controlling) shareholders	(280,578)	(448,151)
Weighted average of number of common shares for diluted losses per share (in thousands)	786,041	776,860
Diluted loss per share - (in R\$)	<u>(0.35695)</u>	<u>(0.57688)</u>

Weighted average of shares (In thousands)

	06/30/2024	06/30/2023
Weighted average of number of shares for basic earnings per share	747,218	746,880
Dilution effect:		
Share purchase option plan	38,823	29,980
Weighted average of the quantity of shares for diluted earnings per share	<u>786,041</u>	<u>776,860</u>

18 Net operating income

The reconciliation between gross income and net operating income presented in the statement of income for the period is presented below:

	Parent Company			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Operating income per segment:				
Diagnoses and care coordination ("BU2")	1,560,403	3,054,844	1,407,015	2,805,633
	<u>1,560,403</u>	<u>3,054,844</u>	<u>1,407,015</u>	<u>2,805,633</u>
Deductions:				
Taxes on billing	(93,714)	(180,937)	(86,007)	(168,095)
Losses from variable consideration (disallowance)	(14,022)	(25,764)	(8,826)	(15,560)
Commercial discounts	(18,788)	(51,569)	(12,108)	(17,710)
Net operating income	<u>1,433,879</u>	<u>2,796,574</u>	<u>1,300,074</u>	<u>2,604,268</u>
	Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Operating income per segment:				
Hospitals and oncology (BU1)	2,221,517	4,324,180	2,002,199	3,894,575
Diagnoses and care coordination ("BU2")	1,964,607	3,856,750	1,830,341	3,651,853
Diagnoses - International Operations ("BU2")	119,892	194,322	87,502	172,810
	<u>4,306,016</u>	<u>8,375,252</u>	<u>3,920,042</u>	<u>7,719,238</u>
Deductions:				
Taxes on billing	(259,120)	(502,316)	(238,379)	(465,569)
Losses from variable consideration (disallowance)	(71,894)	(135,093)	12,155	(18,952)
Commercial discounts	(19,310)	(54,159)	(62,878)	(69,707)
Net operating income	<u>3,955,692</u>	<u>7,683,684</u>	<u>3,630,941</u>	<u>7,165,011</u>

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

For information by business segment (BU1 and BU2), see Note 23.

DASA Group has a concentration among its client portfolios. On June 30, 2024 and 2023, the consolidated concentration of the five main customers is as follows:

	06/30/2024	06/30/2023
CLIENT A	12%	13%
CLIENT B	10%	9%
CLIENT C	11%	8%
CLIENT D	6%	5%
CLIENT E	3%	3%

19 Cost of services rendered

	Parent Company			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Personnel cost	(252,168)	(486,215)	(253,058)	(486,724)
Cost with material	(272,997)	(517,473)	(250,021)	(467,840)
Cost with services and utilities	(307,594)	(607,556)	(255,834)	(523,395)
Depreciation and amortization cost	(89,616)	(180,312)	(97,017)	(195,515)
General expenditures	(17,362)	(32,546)	(15,950)	(29,750)
	(939,737)	(1,824,102)	(871,880)	(1,703,224)

	Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Personnel cost	(816,141)	(1,567,828)	(723,353)	(1,430,543)
Cost with material	(921,265)	(1,793,350)	(824,929)	(1,602,225)
Cost with services and utilities	(807,040)	(1,569,455)	(721,191)	(1,441,840)
Depreciation and amortization cost	(184,480)	(372,335)	(186,179)	(376,348)
General expenditures	(86,956)	(175,418)	(90,822)	(179,042)
	(2,815,882)	(5,478,386)	(2,546,474)	(5,029,998)

20 General and administrative expenses

	Parent Company			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Personnel expenses	(154,254)	(298,465)	(135,797)	(268,375)
Provision for profit sharing and bonus	(24,206)	(45,923)	(28,776)	(57,420)
Stock option plan (Note 16)	(5,233)	(9,553)	(14,019)	(22,943)
Services and utilities	(141,758)	(288,484)	(132,431)	(247,548)
Advertising and publicity	(8,749)	(18,067)	(11,928)	(22,864)
Transportation expenses	(23,556)	(40,730)	(18,486)	(35,294)
Depreciation and amortization	(95,958)	(206,944)	(95,938)	(184,951)
Taxes and rates	(709)	(2,977)	(571)	(2,564)
Impairment loss on accounts receivable	(1,372)	(1,544)	(7,369)	(9,236)
On lending of corporate expenses	114,638	213,771	170,713	170,713
Other	(21,805)	(37,760)	(60,574)	(86,197)
	(362,962)	(736,676)	(335,176)	(766,679)

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Personnel expenses	(261,536)	(506,241)	(258,552)	(512,065)
Provision for profit sharing and bonus	(34,815)	(66,299)	(41,085)	(83,794)
Stock option plan (Note 16)	(2,524)	(8,770)	(18,269)	(30,396)
Services and utilities	(257,108)	(510,745)	(246,859)	(466,416)
Advertising and publicity	(14,336)	(28,715)	(19,502)	(37,401)
Transportation expenses	(24,942)	(43,576)	(20,298)	(38,565)
Depreciation and amortization	(138,000)	(285,607)	(124,212)	(244,038)
Taxes and rates	(5,676)	(11,804)	(4,596)	(12,407)
Impairment loss on accounts receivable	4,834	(12,075)	(17,753)	(26,137)
Other	(83,850)	(135,870)	(91,440)	(145,754)
	(817,953)	(1,609,702)	(842,566)	(1,596,973)

21 Net financial profit (loss)

	Parent Company			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Financial expenses				
Interest on loans and debentures	(317,487)	(637,049)	(332,016)	(733,386)
Interest on right-of-use lease	(23,109)	(45,984)	(20,509)	(42,524)
Interest (a)	(7,011)	(38,915)	3,626	(1,571)
Inflation adjustment in payable - acquisition of subsidiaries	(1,682)	(3,878)	(4,882)	(10,593)
Exchange rate change and inflation adjustment costs	(82,328)	(128,654)	(45,220)	(45,743)
Inflation adjustment of lawsuits	4,861	8,556	15,543	4,411
Intercompany financial profit (loss) (Note 25.d)	242,542	470,740	370,144	370,144
Other	(15,560)	(31,212)	(17,987)	(28,904)
	(199,774)	(406,396)	(31,301)	(488,166)
Financial income				
Interest	31,447	57,273	56,099	106,378
Derivative financial instruments	51,855	76,542	-	-
Exchange rate change and inflation adjustments in assets	(2,890)	(1,632)	5,637	5,586
Other	449	492	-	27
	80,861	132,675	61,736	111,991
	(118,913)	(273,721)	30,435	(376,175)

	Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Financial expenses				
Interest on loans and debentures	(325,149)	(655,527)	(348,952)	(777,081)
Interest on right-of-use lease	(82,735)	(158,922)	(52,305)	(104,707)
Interest (a)	(7,733)	(47,852)	(48,595)	(61,503)
Inflation adjustment in payable - acquisition of subsidiaries	(34,517)	(69,736)	(44,577)	(81,245)
Exchange rate change and inflation adjustment costs	(89,853)	(142,205)	(53,039)	(75,735)
Inflation adjustment of lawsuits	2,778	5,986	15,543	4,342
Other	(22,429)	(45,812)	(25,332)	(58,700)
	(559,638)	(1,114,068)	(557,257)	(1,154,629)
Financial income				
Interest	49,533	91,360	119,111	188,722
Derivative financial instruments	53,966	82,490	(5,786)	(11,138)
Exchange rate change and inflation adjustments in assets	4,134	2,486	(2,250)	(5,446)
Other	930	1,745	1,103	2,550
	108,563	178,081	112,179	174,689
	(451,075)	(935,987)	(445,078)	(979,940)

(a) Other interest expenses include late payment interest, prepayment of receivables, among others.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

22 Income tax and social contribution

Provision for income tax and social contribution on net income, in compliance with the accrual basis.

The combined tax rate, or nominal rate, is 34%, and is in line with current tax legislation.

The reconciliation between the income tax and social contribution expense and respective effective rate of these taxes are presented below:

	Parent Company			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Profit/(loss) before income tax and social contribution	(98,913)	(281,663)	(218,691)	(448,151)
Combined tax rate	34%	34%	34%	34%
Income tax and social contribution:				
Calculated at combined statutory rate	33,630	95,765	74,355	152,371
Permanent (additions) exclusions				
Equity in results of subsidiaries	(43,926)	(92,018)	(113,761)	(67,062)
Non-deductible expenses (a)	(1,607)	(2,662)	26,895	24,226
Expenses from expenditures with issue of shares	-	-	10,003	10,003
Other adjustments				
Taxation on Universal Bases - (TBU 2022)	-	-	-	(17,252)
Constitution of tax loss carryforwards (c)	6,193	-	-	(36,802)
Provision for deferred tax loss	-	-	(67,370)	(67,370)
Other	-	-	6,468	1,886
	(5,710)	1,085	(63,410)	-
Income tax and social contribution - current	(30,501)	(42,350)	-	-
Deferred taxes	24,791	43,435	(63,410)	-
Total	(5,710)	1,085	(63,410)	-
Effective rate (d)	5.8%	-0.4%	29.0%	0.0%
	Consolidated			
	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024	04/01/2023– 06/30/2023	01/01/2023– 06/30/2023
Profit (loss) before income tax and social contribution	(105,399)	(287,066)	(229,707)	(458,546)
Combined tax rate	34%	34%	34%	34%
Income tax and social contribution:				
Calculated at combined statutory rate	35,835	97,602	78,101	155,906
Effect of tax rates in foreign jurisdictions (30%)	7,587	9,954	1,577	(124)
Permanent (additions) exclusions				
Non-deductible expenses (a)	(2,243)	(16,176)	11,364	(3,739)
Expenses from expenditures with issue of shares	-	-	10,003	10,003
Other adjustments				
Presumed tax regime (b)	2,507	5,233	(18,082)	(20,351)
Taxation on Universal Bases - (TBU 2022)	-	-	-	(17,252)
Constitution of tax loss carryforwards (c)	(38,636)	(86,206)	(75,930)	(52,331)
Provision for deferred tax loss	-	-	(67,370)	(67,370)
Other	-	-	5,986	1,996
	5,050	10,407	(54,350)	6,738
Income tax and social contribution - current	(70,064)	(123,275)	16,939	(65,505)
Deferred taxes	75,114	133,682	(71,289)	72,243
Total	5,050	10,407	(54,350)	6,738
Effective rate (d)	-4.8%	-3.6%	23.7%	-1.5%

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

- (a) It refers to expenses that cannot be deducted for tax purposes, under the terms of the applicable tax legislation, such as: expenses with fines, donations, gifts and others;
- (b) Brazilian tax legislation allows the companies that earned gross income of up to R\$ 78 million in their previous fiscal year, to adopt a more simplified taxation regime for IRPJ and CSLL purposes, called presumed tax regime. Some of the Company's subsidiaries adopt this tax regime, according to which the IRPJ and CSLL calculation basis was calculated using a presumed profit rate equivalent to 8% of the operation's income. The presumed tax regime adjustment represents the difference between taxation under this method and what would have been due based on the official tax rate applied to the taxable income of these subsidiaries;
- (c) Refers to deferred IRPJ and CSLL on the balances of tax losses and negative CSLL calculation bases not recorded in the period.
- (d) The effective tax rate on profits is calculated as the ratio between IRPJ and CSLL expenses (current and deferred) and profit (or loss) before IRPJ and CSLL. This is a different percentage from the nominal rate, since taxable profit is calculated through adjustments provided for in tax legislation (called "additions" or "exclusions") to the accounting profit (loss).

Deferred taxes on tax losses and temporary differences

The deferred income tax ("IRPJ") and social contribution ("CSLL") are recognized to reflect future tax effects attributable to temporary differences between the tax bases of assets and liabilities and their book values.

In line with CPC 32/IAS 12 Income taxes, the DASA Group bases its recognition of deferred tax assets and liabilities on temporary differences and tax losses on the expectation of generating future taxable profits, through a technical study approved by Management. Tax losses have no statute of limitations, and their offsetting is legally limited to 30% of taxable profits. Projections for the realization of deferred tax assets are reviewed annually.

Breakdown of balances of deferred income tax and social contribution is as follows:

	Balance sheet Parent Company		Profit (loss) Parent Company	
	06/30/2024	12/31/2023	04/01/2024– 06/30/2024	01/01/2024– 06/30/2024
Tax loss carryforwards	1,067,479	1,085,960	(13,141)	(18,481)
Provision for expected losses from doubtful accounts and provision for disallowance	20,032	17,137	2,939	2,895
Sundry provision and for specialized medical services	47,057	33,387	(2,911)	13,670
Provision for stock option plan	118,143	115,128	1,683	3,015
Provision for variable remuneration, disputes and overtime	26,054	5,193	13,194	20,861
Depreciation IFRS 16 - Leases	23,573	12,846	980	10,727
Provision for obsolescence	(66)	200	(462)	(266)
Adjustment to present value - AVP	2,770	3,459	371	(689)
Provision for ISS on income to be billed	9	-	-	9
Provision for legal disputes	35,340	31,743	9,863	3,597
Adjustment of useful lives of property and equipment	22,895	21,738	919	1,157
Downstream merger of subsidiary	282,695	282,695	-	-
Surplus in the acquisition of subsidiary	30,445	21,090	9,230	9,355
Goodwill Amortization	(704,171)	(700,294)	(1,696)	(3,877)
Other	7,235	5,748	3,847	1,487
Deferred income tax and social contribution	979,490	936,030	24,816	43,460
Changes in equity not affecting profit (loss)			(25)	(25)
Deferred income tax and social contribution	979,490	936,030	24,791	43,435
Balance sheet presentation:				
Deferred tax assets	979,490	936,030		
	979,490	936,030		
Reconciliation of deferred tax assets				
Balance at December 31, 2022	931,905			
Balance at June 30, 2023	931,905			
Balance at December 31, 2023	936,030			
Tax income recognized in profit (loss)	43,435			
Other	25			
Balance at June 30, 2024	979,490			

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Balance sheet Consolidated		Profit (loss) Consolidated	
	06/30/2024	12/31/2023	04/01/2024–06/30/2024	01/01/2024–06/30/2024
Tax loss carryforwards	1,213,616	1,233,952	(14,882)	(20,336)
Provision for expected losses from doubtful accounts and disallowance	147,678	115,414	8,995	32,264
Sundry provision and for specialized medical services	68,036	79,108	(10,185)	(11,072)
Provision for variable remuneration, disputes and overtime	66,009	17,730	25,735	48,279
Provision for stock option plan	118,143	115,128	1,683	3,015
Depreciation IFRS 16 - Leases	79,787	53,472	6,497	26,315
Provision for obsolescence	874	2,051	(921)	(1,177)
Adjustment to present value - AVP	1,517	2,054	371	(537)
Provision for ISS on income to be billed	14,896	10,685	771	4,211
Equity valuation adjustment	22,208	22,575	(975)	(367)
Provision for legal disputes	74,572	28,596	21,917	45,976
Adjustment of useful lives of property and equipment	28,403	26,749	1,292	1,654
Downstream merger of subsidiary	282,695	282,695	-	(0)
Surplus in the acquisition of subsidiary	37,220	21,090	9,904	16,130
Goodwill Amortization	(710,039)	(695,429)	(6,933)	(14,610)
Contingent assets	(73,121)	(72,300)	-	(821)
Revaluation reserve	(896)	(896)	-	-
Other	28,407	30,178	31,400	(1,771)
Deferred income tax and social contribution	1,400,005	1,272,852	74,669	127,153
Changes in equity not affecting profit (loss)			445	6,529
Deferred income tax and social contribution	1,400,005	1,272,852	75,114	133,682
Balance sheet presentation:				
Deferred tax assets	1,420,383	1,286,050		
Deferred tax liabilities	(20,378)	(13,198)		
	1,400,005	1,272,852		
Reconciliation of deferred tax assets				
Balance at December 31, 2022	1,263,829			
Tax income recognized in profit (loss)	71,288			
Other	38,721			
Balance at June 30, 2023	1,373,838			
Balance at December 31, 2023	1,272,852			
Tax income recognized in profit (loss)	133,682			
Other	(6,529)			
Balance at June 30, 2024	1,400,005			

As mentioned, DASA group's Management considers that the balances of deferred income tax and social contribution assets arising from temporary differences will be realized in accordance with the expected generating of future taxable income, based on a technical feasibility study.

DASA Group did not identify cases indicators of non-recovery for deferred taxes as at June 30, 2024.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

23 Information by business segment

For the purposes of analysis and decision making by Management, the DASA Group's operations are managed considering three strategic divisions, which are its reportable segments: (i) outpatient care services and care coordination; (ii) hospitals and oncology - through Ímpar and its subsidiaries and (iii) International operations - auxiliary support services located in Argentina and Uruguay. The operating segment is reported consistently with management reports used by the main operating decision maker (President) to assess segment performance and resource allocation. The President of DASA Group analyzes the internal management reports of each division at least quarterly. The following summary describes the operations of each segment:

Segments	Operations	Geographic region
Hospitals and oncology (BU1)	Medical and hospital services	Brazil
Diagnoses and care coordination ("BU2")	Diagnosis and health management	Brazil
International diagnoses (BU2)	Diagnosis	South America (Argentina and Uruguay)

The segment performance was assessed based on net operating income, net profit (loss) and employed capital (total assets less current and non-current liabilities) in each segment.

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The information for the three-month period ended June 30, 2024 and 2023 is shown below:

	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Total		Discontinued operations (a)	Total except for discontinued operations
	04/01/2024 to 06/30/2024	04/01/2023 to 06/30/2023	04/01/2024 to 06/30/2024	04/01/2023 to 06/30/2023	04/01/2024 to 06/30/2024	04/01/2023 to 06/30/2023	04/01/2024 to 06/30/2024	04/01/2023 to 06/30/2023	04/01/2024 to 06/30/2024	04/01/2024 to 06/30/2024
Net income:										
Income per segment	2,029,719	1,853,612	1,763,252	1,646,036	120,641	85,986	3,913,612	3,585,634	2,632	3,910,980
Intra-segment income	-	-	44,712	45,307	-	-	44,712	45,307	-	44,712
	2,029,719	1,853,612	1,807,964	1,691,343	120,641	85,986	3,958,324	3,630,941	2,632	3,955,692
Cost:										
Reportable segment cost	(1,516,631)	(1,242,240)	(1,168,493)	(1,196,090)	(87,537)	(62,836)	(2,772,661)	(2,501,166)	(1,491)	(2,771,170)
Intra-segment cost	(44,712)	(45,307)	-	-	-	-	(44,712)	(45,307)	-	(44,712)
	(1,561,343)	(1,287,547)	(1,168,493)	(1,196,090)	(87,537)	(62,836)	(2,817,373)	(2,546,473)	(1,491)	(2,815,882)
Results by reportable segments:										
Operating income (expenses), net	(311,344)	(340,931)	(460,598)	(513,736)	(24,048)	(14,979)	(795,990)	(869,646)	(1,856)	(794,134)
Financial income	30,204	63,785	68,899	58,306	10,735	(9,912)	109,838	112,179	1,275	108,563
Financial expenses	(318,960)	(446,095)	(238,997)	(108,268)	(2,760)	(2,894)	(560,717)	(557,257)	(1,079)	(559,638)
Income tax and social contribution	8,519	5,308	(3,470)	(60,083)	(8)	425	5,041	(54,350)	(9)	5,050
	(123,205)	(151,868)	5,305	(128,528)	17,023	(4,210)	(100,877)	(284,606)	(528)	(100,349)
Net profit (loss) by segment										

The information for the six-month periods ended June 30, 2024 and 2023 is shown below:

	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Total		Discontinued operations (a)	Total except for discontinued operations
	01/01/2024 to 06/30/2024	01/01/2023 to 06/30/2023	01/01/2024 to 06/30/2024	01/01/2023 to 06/30/2023	01/01/2024 to 06/30/2024	01/01/2023 to 06/30/2023	01/01/2024 to 06/30/2024	01/01/2023 to 06/30/2023	01/01/2024 to 06/30/2024	01/01/2023 to 06/30/2023
Net income:										
Income per segment	3,953,964	3,609,135	3,439,138	3,291,483	196,019	169,949	7,589,121	7,070,567	4,826	7,584,295
Intra-segment income	-	-	99,389	94,444	-	-	99,389	94,444	-	99,389
	3,953,964	3,609,135	3,538,527	3,385,927	196,019	169,949	7,688,510	7,165,011	4,826	7,683,684
Cost:										
Reportable segment cost	(2,876,186)	(2,549,499)	(2,366,945)	(2,269,149)	(138,459)	(116,906)	(5,381,590)	(4,935,554)	(2,593)	(5,378,997)
Intra-segment cost	(99,389)	(94,444)	-	-	-	-	(99,389)	(94,444)	-	(99,389)
	(2,975,575)	(2,643,943)	(2,366,945)	(2,269,149)	(138,459)	(116,906)	(5,480,979)	(5,029,998)	(2,593)	(5,478,386)
Results by reportable segments:										
Operating income (expenses), net	(597,864)	(565,416)	(923,879)	(1,014,816)	(37,481)	(33,386)	(1,559,224)	(1,613,618)	(2,847)	(1,556,377)
Financial income	36,255	79,236	135,251	107,557	10,830	(12,104)	182,336	174,689	4,255	178,081
Financial expenses	(601,587)	(578,285)	(509,724)	(569,159)	(4,730)	(7,185)	(1,116,041)	(1,154,629)	(1,973)	(1,114,068)
Income tax and social contribution	17,636	16,383	(7,229)	(9,406)	(14)	(239)	10,393	6,738	(14)	10,407

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Net profit (loss) by segment	(167,171)	(82,890)	(133,999)	(369,046)	26,165	129	(275,005)	(451,807)	1,654	(276,659)
	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Total		Discontinued operations (a)	Total except for discontinued operations
	01/01/2024–06/30/2024	01/01/2023–06/30/2023	01/01/2024–06/30/2024	01/01/2023–06/30/2023	01/01/2024–06/30/2024	01/01/2023–06/30/2023	01/01/2024–06/30/2024	01/01/2023–06/30/2023	01/01/2024–06/30/2024	01/01/2024–06/30/2024
Net income:										
Income per segment	3,953,964	3,609,135	3,439,138	3,291,483	196,019	169,949	7,589,121	7,070,567	4,826	7,584,295
Intra-segment income	-	-	99,389	94,444	-	-	99,389	94,444	-	99,389
	3,953,964	3,609,135	3,538,527	3,385,927	196,019	169,949	7,688,510	7,165,011	4,826	7,683,684
Cost:										
Reportable segment cost	(2,876,186)	(2,549,499)	(2,366,945)	(2,269,148)	(138,459)	(116,906)	(5,381,590)	(4,935,553)	(2,593)	(5,378,997)
Intra-segment cost	(99,389)	(94,444)	-	-	-	-	(99,389)	(94,444)	-	(99,389)
	(2,975,575)	(2,643,943)	(2,366,945)	(2,269,148)	(138,459)	(116,906)	(5,480,979)	(5,029,997)	(2,593)	(5,478,386)
Results by reportable segments:										
Operating income (expenses), net	(597,864)	(565,416)	(923,880)	(1,014,816)	(37,481)	(33,386)	(1,559,224)	(1,613,618)	(2,847)	(1,556,377)
Financial income	44,709	79,236	135,251	107,557	10,830	(12,104)	190,791	174,689	4,255	186,535
Financial expenses	(610,041)	(578,285)	(509,723)	(569,159)	(4,730)	(7,185)	(1,124,494)	(1,154,629)	(1,973)	(1,122,522)
Income tax and social contribution	17,636	16,383	(7,230)	(9,406)	(14)	(239)	10,392	6,738	(14)	10,406
Net profit (loss) by segment	(167,171)	(82,890)	(134,000)	(369,045)	26,165	129	(275,004)	(451,806)	1,654	(276,659)

(a) Profit from discontinued operations excluded from the Company's profit (loss).



Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Hospitals and oncology (BU1)		Diagnoses and care coordination ("BU2")		Diagnoses - International Operations ("BU2")		Total	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Total assets	14,683,804	14,221,881	13,128,128	11,827,565	332,786	163,754	28,144,718	26,213,200
Total current and non-current liabilities	6,762,831	6,459,563	14,105,427	12,350,987	105,384	68,831	20,973,642	18,879,381
Parent Company	06/30/2024	06/30/2023	06/30/2024	06/30/2023	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Equity in results of subsidiaries	(170,828)	(92,129)	(125,976)	(105,241)	26,164	129	(270,640)	(197,241)

Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

24 Financial instruments

Accounting classification and fair values

The following table shows the book and fair values of financial assets and liabilities, including their fair value hierarchy. It does not include information on the fair value of financial assets and liabilities not measured at fair value if the book value is a reasonable approximation of fair value.

Parent Company						
				Fair value	Book balance	
				06/30/2024	06/30/2024	12/31/2023
Financial liabilities measured at fair value						
Bank Deposit Certificate and repurchase and resale commitments	5	Fair value through profit or loss	Level 2	1,827,086	1,827,086	405,017
Collateralized by means of interest earning bank deposits	14	Fair value through profit or loss	Level 2	6,728	6,728	6,475
Derivative financial instruments		Fair value through profit or loss	Level 2	58,918	58,918	-
				1,892,732	1,892,732	411,492
Financial assets not measured at fair value						
Cash and banks	5	Financial assets at amortized cost	-	44,118	44,119	116,423
Trading securities	6	Financial assets at amortized cost	Level 2	84,036	84,036	79,561
Trade accounts receivable	7	Financial assets at amortized cost	-	1,108,188	1,189,710	1,013,051
				1,236,342	1,317,865	1,209,035
				3,129,074	3,210,597	1,620,527
Financial liabilities not measured at fair value						
Loans and financing	11	Financial liability at amortized cost	-	8,808	9,461	11,958
Debentures	13	Financial liability at amortized cost	-	11,377,716	11,130,111	10,258,035
Suppliers		Financial liability at amortized cost	-	499,463	543,255	675,540
Payable - acquisition of subsidiaries	14	Financial liability at amortized cost	-	104,770	101,212	137,849
Lease liabilities	12	Financial liability at amortized cost	-	904,092	904,092	928,001
				12,894,849	12,688,131	12,011,383
Financial liabilities measured at fair value						
Contingent consideration	14	Fair value through profit or loss	Level 3	9,378	9,378	8,557
				9,378	9,378	8,557
				12,904,227	12,697,509	12,019,940

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

Consolidated							
					Fair value	Book balance	
					06/30/2024	06/30/2024	12/31/2023
Financial liabilities measured at fair value	Note	Classification per category	Hierarchy				
Interest earning bank deposits	5	Fair value through profit or loss	Level 2		2,194,976	2,194,976	1,146,286
Collateralized by means of interest earning bank deposits	14	Fair value through profit or loss	Level 2		7,388	7,388	6,605
Derivative financial instruments		Fair value through profit or loss	Level 2		72,031	72,031	7,165
					2,274,395	2,274,395	1,160,056
Financial assets not measured at fair value							
Cash and banks	5	Financial assets at amortized cost	-		677,725	677,725	438,908
Trading securities	6	Financial assets at amortized cost	Level 2		113,721	113,721	103,815
Trade accounts receivable	7	Financial assets at amortized cost	-		4,473,029	4,744,211	3,992,580
					5,264,475	5,535,657	4,535,303
					7,538,870	7,810,052	5,695,359
Financial liabilities not measured at fair value							
Loans and financing	11	Financial liability at amortized cost	-		101,673	116,387	192,270
Debentures	13	Financial liability at amortized cost	-		11,471,175	11,230,653	10,459,167
Suppliers		Financial liability at amortized cost	-		1,251,461	1,336,284	1,584,985
Payable - acquisition of subsidiaries	14	Financial liability at amortized cost	-		1,019,947	1,184,941	1,199,248
Lease liabilities	12	Financial liability at amortized cost	-		2,582,759	2,582,759	2,643,191
					16,427,015	16,451,024	16,078,861
Financial liabilities measured at fair value							
Contingent consideration	14	Fair value through profit or loss	Level 3		68,521	68,521	67,700
					68,521	68,521	67,700
					16,495,536	16,519,545	16,146,561

In the measurement, the book value represents a reasonable approximation of the fair value, as described below:

(i) The balances of cash and cash equivalents, trade accounts receivable, trade accounts payable and other current liabilities are equivalent to their book values, mainly due to the short-term maturity of these instruments;

(ii) The balances of Bank Deposit Certificates and Repo Operations are measured at fair value against the statement of income, taking into account the rates agreed between the parties when contracting the investments, including market information that makes this calculation possible. Securities are measured at amortized cost and approximate their fair values because the transactions are carried out at floating interest rates;

(iii) The book values of loans, financing and debentures are measured at their amortized cost and disclosed at fair value, which does not differ materially from the book value to the extent that the interest agreed is consistent with current market rates.

Different levels are defined as follows:

- Level 1 - Prices quoted (not adjusted) in active markets for identical assets and liabilities.
- Level 2 – Inputs, in addition to quoted prices, included in level 1 that is observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions, for assets or liabilities, which are not based on observable market data (non-observable data).

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Foreign exchange risk

Through the subsidiary Ímpar, DASA Group assumed loans contracted for in foreign currency (US Dollar) that have derivative financial instruments contracted for protection against changes foreign exchange rate.

As of June 30, 2024, DASA Group had derivative contracts to hedge the exchange rate fluctuations for all outstanding foreign currency loans. Summaries of the contracts in force are as follows:

Interest rate swap (fixed CDI rate)	Nominal value (US\$'000)	Balance of loans as of 06/30/2024	Original indexes	Swap	Start	Maturity	Unrealized gains (losses) from derivative instruments on 06/30/2024
Santander	9,147	50,838	4.45%	CDI+1.35%	11/12/2019	10/04/2024	13,113
							13,113

Consolidated

	06/30/2024		12/31/2023	
	Current	Total	Non-current	Total
Swap				
Assets	13,113	13,113	7,165	7,165
Liabilities	-	-	(1,505)	(1,505)
	13,113	13,113	5,660	5,660

Market risk

The Company has entered into derivative contracts to convert the National Amplified Consumer Price Index ("IPCA") indicator of certain loans into the CDI indicator, as follows:

Interest rate swap (IPCA to CDI)	Nominal value (US\$'000)	Balance of loans as of 06/30/2024	Original indexes	Swap	Start	Maturity	Unrealized gains (losses) from derivative instruments on 06/30/2024
XP	419,184	460,373	IPCA+6.60%	CDI+1.05%	05/24/2023	10/15/2029	(32,134)
Itaú	247,482	271,878	IPCA+6.75%	CDI+1.22%	11/11/2022	10/15/2032	(7,203)
XP	551,248	578,015	Fixed rate 12.30%	CDI+1.97%	02/01/2024	01/15/2029	(39,252)
XP	124,430	130,911	IPCA+7.34%	CDI+1.96%	02/01/2024	01/15/2031	(7,589)
Itaú	690,427	725,398	Fixed rate 12.85%	CDI+2.36%	02/02/2024	01/15/2031	58,900
XP	210,090	221,326	IPCA+7.61%	CDI+2.13%	02/01/2024	01/16/2034	(16,545)
							(43,823)

Consolidated

	06/30/2024			12/31/2023		
	Current	Non-current	Total	Current	Non-current	Total
Swap						
Assets	18	58,900	58,918	-	-	-
Liabilities	(934)	(101,807)	(102,741)	(885)	(23,601)	(24,486)
	(916)	(42,907)	(43,823)	(885)	(23,601)	(24,486)

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Liquidity risk

DASA group manages liquidity risk by maintaining proper reserves, bank credit facilities and credit facilities to raise loans as it considers adequate, through continuous monitoring of foreseen and actual cash flows and through combination of financial assets and liabilities' maturity profiles by allocating:

- a) Short-term cash management - Management of liquid assets and credit facilities to cover immediate needs.
- b) Long-term cash management - Ongoing process to guarantee long-term funds, by analyzing the cash budget on a monthly basis, updating the budgeted assumptions according to the needs of the business, and comparing the actual versus budgeted amounts.
- c) Maintenance of a minimum cash – Refers to the cash balance that DASA group covers in a very short time to meet its urgent needs. Furthermore, the Company adopts as a criterion that the cash must have sufficient funds to cover the five worst daily flows of a particular month, without considering receipts.
- d) Exposure limits and risk mitigators - The treasury area maintains, in short-term lines, between cash investments with immediate liquidity and working capital facilities, a volume of funds sufficient to guarantee at least the amount equal to the five largest consecutive days of cash disbursements in the last 12 months.

For medium-term and long-term facilities, the treasury department credit facilities compatible with DASA group's strategic planning, always with the goal of guaranteeing the availability of funds to fulfill the expected cash flow.

The table below shows the maturities of consolidated non-current (undiscounted) financial liabilities contracted in detail (the balances of short-term instruments shown below are undiscounted, once that maturities are on short-term basis):

06/30/2024

Operation	1–2 years	2–3 years	3–4 years	>4 years	Total
Derivative financial instruments	101,807	-	-	-	101,807
Suppliers	16,548	-	-	-	16,548
Loans and financing	11,866	10,806	-	-	22,672
Debentures	1,006,141	3,403,936	3,068,917	6,372,291	13,851,285
Leases	167,322	341,502	333,525	1,311,315	2,153,664
Share-based payment	6,058	-	-	-	6,058
Payable - acquisition of subsidiaries	121,092	142,488	619,318	65,911	948,809
	1,430,834	3,898,732	4,021,760	7,749,517	17,100,843

12/31/2023

Operation	1–2 years	2–3 years	3–4 years	>4 years	Total
Derivative financial instruments	25,106	-	-	-	25,106
Suppliers	46,743	-	-	-	46,743
Loans and financing	37,628	15,514	-	-	53,142
Debentures	1,961,745	3,545,210	7,078,439	-	12,585,394
Leases	175,940	359,092	350,704	1,378,856	2,264,592
Share-based payment	21,954	-	-	-	21,954
Payable - acquisition of subsidiaries	183,720	578,082	-	-	761,802
	2,452,836	4,497,898	7,429,143	1,378,856	15,758,733

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

Sensitivity analysis for financial assets and liabilities

In order to check the sensitivity of the index of consolidated interest earning bank deposits on the base date of June 30, 2024, scenarios based on projection and were defined and changes of 25% and 50% were calculated.

For each scenario the financial expense/gross (financial income) was calculated, taking into account the flow of maturities for each contract scheduled for 2024, excluding the taxes levied. As it does not generate financial profit (loss), investments that guarantee the payments of lawsuits that may be required from acquired companies R\$ 6,728 as of June 30, 2024 were not considered in this projection.

Operation	Balance at 06/30/2024	Risk (a)	Scenario I	Scenario II	Scenario III
			(Probable)		
Cash and cash equivalents/Securities	2,979,694	CDI	309,473	232,105	154,737
	Rate subject to change	CDI	10.39%	7.79%	5.19%

In order to check the sensitivity of the index of debts in the consolidated on the base date of June 30, 2024, three scenarios based on projection and were defined and changes of 25% and 50% were calculated.

For each scenario the gross financial expense was calculated, taking into account the flow of maturities for each contract scheduled for 2024, excluding the taxes levied. The base date used for financings was June 30, 2024, projecting indices for one year and verifying their sensitivity in each scenario.

Operation	Balance at 06/30/2024	Risk (a)	Scenario I	Scenario II	Scenario III
			(Probable)		
Debentures	11,230,653	CDI	1,166,424	1,458,030	1,749,636
	Rate subject to change	CDI	10.39%	12.98%	15.58%

Capital management

The financial leverage ratios can be summarized as follows:

	06/30/2024	12/31/2023
Total gross debt	11,347,040	10,651,437
Total cash and cash equivalents and securities	(2,986,422)	(1,689,009)
Net balance of derivative transactions	30,710	18,826
Net debt	8,391,328	8,981,254
Shareholders' equity	7,150,829	7,330,427
Total capital	15,542,157	16,311,681
Leverage ratio	54.0%	55.1%

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

25 Related parties

The Company had operations with related parties, as follows:

(a) Operations subsidiaries to the provision of services carried out between the Company and its subsidiaries

	Current assets Trade accounts receivable		Current liabilities - Other accounts payable		Net operating income		Cost of services rendered	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Bioclinico	3,591	3,328	-	-	1,058	825	-	-
Chromatox	-	-	2	2	-	-	-	-
CientificaLab	16,007	10,962	-	-	8,871	5,701	-	86
CPClin	53	68	-	-	61	166	-	-
CRMI Petrópolis	-	-	-	1,314	-	-	-	784
DASA RE (a)	-	-	-	-	-	-	393	382
DB Genética	-	-	3,942	-	-	-	4,145	-
Deliberato	4,929	2,874	-	-	2,265	972	-	-
Exame	1,461	1,658	-	-	1,805	2,339	-	-
Gaspar	-	-	-	-	-	-	-	-
Genia - MOL	130	130	-	-	-	-	-	-
Genia Argentina	2,302	715	-	-	1,587	312	-	-
Genia Chile	168	79	-	-	90	61	-	-
Genia Colombia	13	11	-	-	1	8	-	-
Hemat	163	205	-	-	176	257	-	-
Ímpar	8,579	9,348	-	-	33,841	41,802	-	-
Itulab	1,466	378	-	-	1,175	377	-	-
Lustosa	135	730	-	-	929	50	-	-
Mantris	133	134	-	-	-	112	-	-
Nobeloy	477	475	-	-	3	180	-	-
Padrão Ribeirão	656	442	-	-	221	400	-	-
Previlab	13,980	11,254	-	-	3,503	5,595	-	-
Ruggeri	1,718	1,935	-	-	536	646	-	-
Salomão Zoppi	20,922	12,933	-	-	20,932	12,106	-	-
Santa Luzia	91	91	-	-	-	1,840	-	1
São Camilo	182	175	-	-	118	47	-	-
São Marcos	4,331	3,534	-	-	5,836	7,558	-	-
Valeclin	6,607	6,025	4,691	4,967	717	1,817	3,766	2,683
	88,094	67,484	8,635	6,283	83,725	83,171	8,304	3,936

(a) Amounts corresponding to property rental transactions

Related party transactions, as presented above, are carried out at cost and are eliminated in the consolidated financial statements.

(b) Related parties - Loan agreements between the Company and its subsidiaries

	Remuneration fee	Maturity	06/30/2024	12/31/2023
Loan agreement				
Boris	120% CDI	06/02/2025	25,559	24,045
CRMI Petrópolis	120% CDI	10/06/2025	191	180
DB Genética	120% CDI	07/10/2026	69,701	65,131
GSC	120% CDI	01/29/2027	158,789	131,091
Hemat	120% CDI	01/19/2027	6,493	4,751
Lunav	120% CDI	10/25/2025	3,266	3,073
Padrão Ribeirão	120% CDI	11/25/2026	8,342	7,849
			272,341	236,120

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The loan agreements between the Company and its subsidiaries generated financial income, eliminated upon consolidation, of R\$ 20,095 for the period ended June 30, 2023 (R\$ 12,853 as of June 30, 2023).

(c) Related parties - The balances of dividends and interest on own capital receivable by the Company from its subsidiaries are presented below:

	06/30/2024	12/31/2023
Bioclínico	7,163	7,163
Chromatox	14,618	14,618
CP Clin	3,143	3,143
DASA RE	2,463	2,463
Deliberato	2,589	2,589
HEMAT	1,951	1,951
Ímpar	91,215	91,215
Petrópolis	1,074	1,074
Previlab	11,584	11,735
Ruggeri & Piva	4,856	4,856
Valeclin	1,739	1,739
	142,395	142,546

(d) Related parties – Other receivables (Current Assets)

As of 2023, the Company implemented a corporate expense transfer process, from the Parent Company to the Subsidiaries. These on lendings involve corporate expenses that the Parent Company initially assumes and then repasses to the subsidiaries. The amounts were recorded as related parties in non-current assets, totaling R\$ 1,793,911 as of June 30, 2024 (R\$ 1,190,438 as of December 31, 2023).

Additionally, the Company also calculated the specialized medical services shared between the subsidiary Salomão and Zoppi, which were recorded under "Related Parties" in non-current assets, totaling R\$ 63,450 as of June 30, 2024 (R\$ 69,121 as of December 31, 2023).

(e) Management remuneration

Expenses related to the remuneration of key management personnel, including the Board of Directors, the Audit Board and the Statutory Executive Board, recognized in the statement of income, are shown in the table below:

	06/30/2024			12/31/2023		
	Board of Directors	Statutory Board	Total	Board of Directors	Statutory Board	Total
Fixed remuneration (Salary/Directors' fees)	4,430	9,690	14,120	8,936	14,484	23,420
Variable remuneration	-	10,073	10,073	-	15,237	15,237
Share-based compensation	2,042	3,522	5,564	-	2,974	2,974
Total	6,472	23,285	29,757	8,936	32,694	41,630
Benefits	-	725	725	-	371	371
Number of members (average)	6	13		7	13	

The variable remuneration includes performance, hiring, and termination bonuses. The benefits include medical assistance, meal vouchers, food vouchers, and allowance.

Changes in the Administrators' stock option plans are included in Note 16.

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

(f) Controlling shareholder's contribution

On June 10, 2024, the controlling shareholder made a capital contribution in the amount of R\$ 1.5 billion through a Private Instrument of Advance for Future Capital Increase, as presented in Note 2.b.

(g) Other related party balances

Operations carried out between related parties are carried out at usual market values, terms and rates agreed among the parties, in effect on the respective dates and in continuity conditions.

Company	Relationship
A e C Consultores Ltda	Provision of consulting and advisory services
Amar Administradora de Bens Próprios Ltda	Real estate rent
BFL Empreendimentos Imobiliários Ltda	Real estate rent
César Antonio Biazio Sanches	Real estate rent
CM Hospitalar S.A.	Provider of hospital service
Conexa Saúde Serviços Médicos Ltda	Service provider
Ecolimp Sistemas de Serviços Ltda	Service provider
ECRD - Serviços Médicos de Radiologia Ltda	Provision of medical services
EDAN Serviços De Coleta Ltda	Franchise agreement
Essijota Serviços de Coleta e Diagnósticos Ltda	Franchise agreement
José de Oliveira Domingos	Real estate rent
Link Consultoria em Medicina Diagnóstica Ltda	Provision of consulting and advisory services
Localiza Rent a Car S.A.	Vehicle rental
Patrys Investimentos Imobiliários Ltda	Real estate rent
Pesmed - Pesquisas e Serviços Médicos Ltda	Provision of medical services
PTR 7 Investimentos Imobiliários Ltda	Lease of properties
RMR Ressonância Magnética Ltda	Provision of medical services
Seven Seas Partner - Saúde e Prevenção Ltda.-ME	Service provider
Signo Properties Investimentos Imobiliários Ltda	Real estate rent
Socec Serviços Médicos SS Ltda	Real estate rent
VIDA - Posto de Coleta Ltda	Franchise agreement

Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

The following are the amounts of the operations carried out:

	Balances of Assets / (Liabilities)			Balances of Assets / (Liabilities)		
	06/30/2024			12/31/2023		
	Services	Rentals	Other	Services	Rentals	Other
- 3G Empreendimentos e Participações Ltda.	-	-	-	(606)	-	-
- A e C Consultores Ltda.	(23)	-	-	(17)	-	-
- Agaesse Servicos Ltda.	-	-	-	(57)	-	-
- Amar Admin. de Bens Próprios Ltda.	-	(37)	-	-	(37)	-
- BFL Empreendimentos Imobiliários Ltda.	-	(222)	-	-	(213)	-
- César Antonio Biazio Sanches	-	(7)	-	-	(7)	-
- CM Hospitalar (a)	-	-	(63,939)	-	-	(15,379)
- Cm Tecnologia S.A.	(16)	-	-	(16)	-	-
- Conexa Saúde Serviços Médicos Ltda.	(2)	-	-	(15)	-	-
- Connectcom Tecnologia.	-	-	-	(3)	-	-
- Copa Serviços de Coleta e Diagnósticos Ltda.	(141)	-	-	(118)	-	-
- Dmg Laboratório Médico Ltda.	(129)	-	-	(113)	-	-
- Ecolimp Sistemas de Serviços Ltda.	(2,489)	-	-	(169)	-	-
- Edan Servicos de Coleta.	-	-	-	(94)	-	-
- Essijota Serv. de Coleta e Diag. Ltda.	-	-	-	(88)	-	-
- Hro - Hospital de Referência Oftalmológica Ltda.	(8)	-	-	-	-	-
- José de Oliveira Domingues	-	(20)	-	-	(12)	-
- Link Consult. em Medicina Diag. Ltda.	(11)	-	-	(17)	-	-
- Localiza Rent a Car S.A.	(22)	-	-	(28)	-	-
- Mega Copa Serviços de Coleta e Diagnósticos Ltda.	(62)	-	-	(64)	-	-
- Meier Serviços de Coleta e Diagnósticos Ltda.	(33)	-	-	(53)	-	-
- Pechincha Serviços de Coleta e Diagnósticos Ltda.	-	-	-	(138)	-	-
- Phd Servicos de Coleta Ltda.	-	-	-	(116)	-	-
- PTR7 Investimentos Imobiliários Ltda.	-	(1,963)	-	-	(1,918)	-
- PTR14 Investimentos Imobiliários S.A.	-	-	-	-	(2,129)	-
- Seven Seas Partner Saúde e Prev. Ltda.	(103)	-	-	(86)	-	-
- VIDA - Posto de Coleta Ltda.	-	-	-	(95)	-	-
	(3,039)	(2,249)	(63,939)	(1,893)	(4,316)	(15,379)

(a) Related to the purchase of hospital inputs

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Income / (Expenses) 06/30/2024			Income / (Expenses) 06/30/2023		
	Services	Rentals	Other	Services	Rentals	Other
- 3G Empreendimentos e Participações Ltda.	(4,242)	-	-	-	-	-
- A e C Consultores Ltda.	(192)	-	-	(143)	-	-
- Agaesse Servicos Ltda.	(360)	-	-	-	-	-
- Amar Admin. de Bens Próprios Ltda.	-	(219)	-	-	(219)	-
- BFL Empreendimentos Imobiliários Ltda.	-	(1,323)	-	-	(1,213)	-
- César Antonio Biazio Sanches	-	(48)	-	-	(57)	-
- CM Hospitalar (a)	-	-	(15,757)	-	-	(36)
- Cm Tecnologia S.A.	(91)	-	-	-	-	-
- Copa Serviços de Coleta e Diagnósticos Ltda.	(767)	-	-	-	-	-
- Dmg Laboratório Médico Ltda.	(723)	-	-	-	-	-
- Conexa Saúde Serviços Médicos Ltda.	(51)	-	-	(22)	-	-
- Connectcom Tecnologia.	(7)	-	-	-	-	-
- Ecolimp Sistemas de Serviços Ltda.	(24,845)	-	-	(4,355)	-	-
- ECRD Serv. Médicos de Radiologia Ltda.	(1,199)	-	-	(1,099)	-	-
- EDAN Serviços de Coleta Ltda	(1,127)	-	-	(712)	-	-
- Essijota Serv. de Coleta e Diag. Ltda.	(438)	-	-	(416)	-	-
- Hro - Hospital de Referência Oftalmológica Ltda.	(93)	-	-	-	-	-
- José de Oliveira Domingues	-	(118)	-	-	(113)	-
- Link Consult. em Medicina Diag. Ltda.	(197)	-	-	(147)	-	-
- Localiza Rent a Car S.A.	(127)	-	-	(18)	-	-
- Mega Copa Serviços de Coleta d Diagnósticos Ltda.	(354)	-	-	-	-	-
- Meier Serviços de Coleta E Diagnósticos Ltda.	(234)	-	-	-	-	-
- Patrys Investimentos Imobiliários Ltda.	-	(63,460)	-	-	(10,229)	-
- Pesmed – Pesq. e Serv. Médicos Ltda.	(437)	-	-	(307)	-	-
- PTR7 Investimentos Imobiliários Ltda.	-	(11,735)	-	-	(11,778)	-
- RMR Ressonância Magnética Ltda.	(1,273)	-	-	(1,221)	-	-
- Socec Empreendimentos Imobiliários Ltda	-	-	-	-	(379)	-
- Seven Seas Partner Saúde e Prev. Ltda.	(529)	-	-	(520)	-	-
- Signo Properties Invest. Imobiliários Ltda.	-	(2,145)	-	-	-	-
- Ultrascan Serviços de Imagem Ltda.	(46)	-	-	(64)	-	-
- VIDA - Posto de Coleta Ltda.	(691)	-	-	(656)	-	-
- VK Saúde	(387)	-	-	-	-	-
	(38,410)	(79,048)	(15,757)	(9,680)	(23,988)	(36)

(a) Related to the purchase of hospital inputs

These companies are the same as those disclosed in the financial statements for the year ended December 31, 2023.

26 Insurance coverage

As of June 30, 2024, the total insurance coverage was R\$ 7,555,337, and R\$ 739,380 for loss of profits, R\$ 6,663,957 for property damage and R\$ 2,000 for professional civil liability and R\$ 150,000 for professional liability of Directors & Officers (D&O), among others. Assessment of the sufficiency of insurance coverage is not part of the scope of the independent auditors.

27 Discontinued operations

The assets and liabilities related to Nobeloy, Optiren, Genia Argentina, Genia Chile, and Genia Colombia are presented as discontinued operations, following the approval of the discontinuation of these businesses by the DASA Group's Management and shareholders. Operations are scheduled to cease in their entirety in 2024. The breakdown of the balance sheet and statement of income as of June 30, 2024 for discontinued operations is as follows:

Notes to the individual parent company and consolidated quarterly information as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

	Nobeloy	Optiren	Genia Argentina	Genia Chile	Genia Colombia	Eliminations	Total
CURRENT ASSETS							
Cash and cash equivalents	194	(573)	3,208	124	-	-	2,953
Trade accounts receivable	108	8,416	2,041	168	34	-	10,767
Inventories	-	-	804	-	-	-	804
Recoverable taxes	1,040	-	416	-	15	-	1,471
Prepaid expenses	-	-	-	28	-	-	28
Other credits	238	251	576	-	32	-	1,097
TOTAL CURRENT ASSETS	1,580	8,094	7,045	320	81	-	17,120
NON-CURRENT ASSETS							
NON-CURRENT RECEIVABLES							
Deferred taxes	-	-	302	-	-	-	302
Judicial deposits	66	-	-	27	-	-	93
Related parties	4,277	540	-	-	-	(4,822)	(5)
Other credits	-	-	28	-	-	-	28
NON-CURRENT RECEIVABLES	4,343	540	330	27	-	(4,822)	418
Investments	-	6	-	-	-	-	6
Property and equipment	-	-	2,521	73	18	-	2,612
TOTAL NON-CURRENT ASSETS	-	6	2,521	73	18	-	2,618
TOTAL ASSETS	5,923	8,640	9,896	420	99	(4,822)	20,156
CURRENT LIABILITIES							
Suppliers	771	29	3,183	107	-	-	4,090
Social charges and labor obligations	740	34	324	453	-	-	1,551
Income tax and social contribution	-	-	4,192	-	-	-	4,192
Taxes and contributions payable	143	4	217	1	-	-	365
Advance from clients	-	-	-	2	-	-	2
Other accounts payable and provisions	7,986	-	10,128	564	-	(10,646)	8,032
TOTAL CURRENT LIABILITIES	9,640	67	18,044	1,127	-	(10,646)	18,232
NON-CURRENT LIABILITIES							
Deferred taxes	-	-	37	-	-	-	37
TOTAL NON-CURRENT LIABILITIES	-	-	37	-	-	-	37
TOTAL LIABILITIES	9,640	67	18,081	1,127	-	10,646	18,269

	Nobeloy	Optiren	Genia Argentina	Genia Chile	Genia Colombia	Eliminations	Total
Net operating income	-	-	3,760	1,122	-	(56)	4,826
Cost of services rendered	(113)	(72)	(3,580)	(200)	-	1,372	(2,593)
Gross profit/(loss)	(113)	(72)	180	922	-	1,316	2,233
General and administrative expenses	(86)	(44)	(1,872)	(909)	(11)	-	(2,922)
Other income and (expenses), net	-	-	4	71	-	-	75
Profit/(loss) before financial result and taxes	(199)	(116)	(1,688)	84	(11)	1,316	(614)
Financial income	32	295	3,908	20	-	-	4,255
Financial expenses	(12)	(7)	(1,934)	(20)	-	-	(1,973)
Net financial income (expenses)	20	288	1,974	-	-	-	2,282
Profit (loss) before income tax and social contribution	(179)	172	286	84	(11)	1,316	1,668
Income tax and social contribution	(14)	-	-	-	-	-	(14)
Profit/(loss) for the period	(193)	172	286	84	(11)	1,316	1,654

Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024

(In thousands of reais, unless otherwise indicated)

28 Cash flow supplementary information

Statements of cash flows, by the indirect method, are prepared and presented in accordance with the accounting pronouncement CPC 03 (R2) / IAS 07 – Statement of Cash Flows.

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Acquisitions of property and equipment and intangible assets:				
Total acquisitions of property and equipment and intangible assets	80,589	305,062	138,292	441,126
With cash effect	67,397	262,654	119,908	397,305
No cash effect	13,192	42,408	18,384	43,821
Non-cash leases - Additions and remeasurements				
Right-of-use	90,451	48,878	126,286	95,441
Lease liabilities	(90,451)	(48,878)	(126,286)	(95,441)

**Notes to the individual parent company and consolidated quarterly information
as of June 30, 2024**

(In thousands of reais, unless otherwise indicated)

Lício Tavares Ângelo Cintra
Chief Executive Officer

André Covre
Chief Financial Officer

Evandro Luis Rezera
Chief Tax Controlling Officer

Rodrigo Veronezzi Miqueletti
Accounting manager
CRC 1SP269235/O-9